KR102503295B1 - Combinations for preventing or treating cancer comprising novel ethene compound - Google Patents

Abstract

The present invention relates to an ethene compound having a novel structure, a pharmaceutically acceptable salt thereof, or an N-oxide thereof that acts as an ERRβ/γ inverse agonist; And it relates to a combination preparation for preventing or treating cancer including an anticancer agent.

Description

Combination preparations for preventing or treating cancer comprising a novel ethene compound

The present invention relates to an ethene compound having a novel structure, a pharmaceutically acceptable salt thereof, or an N-oxide thereof that acts as an ERRβ/γ inverse agonist; And it relates to a combination preparation for preventing or treating cancer including an anticancer agent.

Estrogen-related receptors (ERRs), such as ERRα, ERRβ, and ERRγ, are orphan nuclear receptors that can regulate transcriptional levels by identifying ERR response elements in target gene promoters. Many reports have described its biological role in regulating oxidative metabolism, energy expenditure and mitochondrial beta oxidation. Conventionally, it has been reported to exhibit antidiabetic effects such as alleviating hyperglycemia and insulin resistance by inhibiting the activity of ERRγ and therapeutic effects of retinopathy.

Recently, several research groups have reported the important role of ERRβ/γ in cancer development, such as breast, gastric, and prostate cancer. Expression of ERRβ is decreased in breast carcinoma compared to adjacent normal breast tissue, and upregulation of ERRγ expression in breast cancer has been shown to be associated with breast cancer treatment. In contrast, the expression of ERRγ in prostate cancer was higher than in benign cancer. According to these reports, ERRβ/γ can be considered as an attractive therapeutic target for various types of cancer. Accumulated research results have shown an important interaction between ERRβ/γ and cancer development, but there is still a need for research on anticancer agents that can selectively remove only cancer cells without affecting normal cells in the body. It is becoming.

WO 2014-151899 A1 (2014.09.25) WO 2020-106933 A1 (2020.05.28)

Oncogene 32(30):3483-3490. The Journal of steroid biochemistry and molecular biology 157:13-19.

Accordingly, the present inventors, while conducting research to evaluate the therapeutic potential of ERRβ/γ in cancer, synthesized an ethene compound with a novel structure that has high biocompatibility, high selectivity, and can act as an orally bioavailable ERRβ/γ inverse agonist. And they confirmed that they can be used as new anticancer agents by showing anticancer effects in cancer, particularly intractable cancer models in vitro and in vivo, and completed the present invention.

An object of the present invention is to provide an ethene compound with a novel structure, a pharmaceutically acceptable salt thereof, or an N-oxide thereof capable of acting as an ERRβ/γ inverse agonist.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer comprising the ethene compound, a pharmaceutically acceptable salt thereof, or an N-oxide thereof as an active ingredient.

Another object of the present invention is the ethene compound, a pharmaceutically acceptable salt thereof or an N-oxide thereof; And to provide a combination preparation for preventing or treating cancer containing an anticancer agent.

Another object of the present invention is to provide a method for treating cancer, comprising administering the ethene compound, a pharmaceutically acceptable salt thereof, or an N-oxide thereof to a subject or subject in need thereof.

Another object of the present invention is to provide the above ethene compound, a pharmaceutically acceptable salt thereof or an N-oxide thereof for use in the treatment of cancer.

Another object of the present invention is to provide the use of the ethene compound, its pharmaceutically acceptable salt or its N-oxide for use in the manufacture of a medicament for the treatment of cancer.

In order to achieve the above purpose,

One aspect of the present invention provides an ethene compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof as a novel compound capable of acting as an ERRβ/γ inverse agonist:

[Formula 1]

In Formula 1,

R ¹ is C1-C20 alkyl or C3-C20 cycloalkyl;

R ² is C1-C20 alkyl, halogen, C3-C20 cycloalkyl, -L ^a1 -R ^a1 , -NR ^a2 R ^a3 , nitro or cyano;

L ^a1 is O or S;

R ^a1 is hydrogen, C1-C20 alkyl, haloC1-C20 alkyl, C3-C20 cycloalkyl, C1-C20 alkoxyC1-C20 alkyl, C1-C20 alkylthioC1-C20 alkyl or C1-C20 alkylcarbonyl;

R ^a2 and R ^a3 are each independently hydrogen, C1-C20 alkyl, C3-C20 cycloalkyl or C6-C20 aryl;

A ¹ to A ⁴ are each independently CR ^a4 or N;

R ^a4 is hydrogen or hydroxy;

R ³ is hydrogen, C1-C20 alkyl or C3-C20 cycloalkyl;

L is CR ^a5 or N;

R ^a5 is hydrogen or C1-C20 alkyl;

m is an integer from 1 to 5, and when m is an integer of 2 or greater, R ₂ may be the same or different;

n is an integer of 0 or 1;

The alkyl of R ₂ and R ³ may be further substituted with one or more selected from the group consisting of halogen, C1-C20 alkyl, C1-C20 alkoxy, hydroxy, amino, mono- or di-C1-C20 alkylamino.

Another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the ethene compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof as an active ingredient.

Another aspect of the present invention is an ethene compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof; And it provides a combination preparation for preventing or treating cancer containing an anticancer agent.

Another aspect of the present invention provides a method for treating cancer, comprising the step of administering the ethene compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof to a subject or subject in need thereof. .

Another aspect of the present invention provides an ethene compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof for use in the treatment of cancer.

Another aspect of the present invention provides a use of the ethene compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof for use in the preparation of a drug for cancer treatment.

The ethene compound of the present invention has high biocompatibility and high selectivity and can act as an orally bioavailable ERRβ/γ inverse agonist. In addition, since the ethene compound of the present invention can specifically induce apoptosis in cancer cell lines by acting as an ERRβ/γ inverse agonist without exhibiting toxicity to normal cells, it is effective against various cancer diseases caused by abnormal cell growth. It can be usefully used as an improvement, prevention, and treatment without side effects.

The pharmaceutical composition for preventing or treating cancer containing the ethene compound of the present invention as an active ingredient exhibits low cytotoxicity and selectively exhibits high inhibitory activity and antiproliferative effect on cancer cells, and thus is useful for preventing or treating cancer. can be used

The pharmaceutical composition for preventing or treating cancer containing the ethene compound of the present invention as an active ingredient is an intractable drug selected from the group consisting of ovarian cancer, prostate cancer, breast cancer, neuroblastoma, glioblastoma, anaplastic thyroid cancer, dedifferentiated thyroid cancer, and colorectal cancer. It can be usefully used for the prevention or treatment of cancer. In addition, the ethene compound of the present invention can be used alone or in combination for the prevention or treatment of cancer.

Figure 1 shows the expression levels of ERRβ and ERRγ in normal and colon cancer tissues [(A and B) upregulated ERRβ/γ expression in colon cancer tissues (ERRβ/γ expression levels in normal and tumor tissues are determined). Western blot analysis was performed to do this); (C) TMA analysis for evaluation of ERRβ/γ expression levels in human colon cancer and normal colon tissues using a commercially available tumor microarray (BC051110c containing 12 normal tissues and 108 tumor tissues) derived from colon cancer patients; P=0.000 compared to normal tissue].
Figures 2 to 6 show the inhibition of proliferation of compound 1 (DN203368)-treated colon cancer cells [(Figure 2) endogenous expression of ERRβ/γ in colon cancer cells, namely HCT116, RKO, SW480 and CT26 cells; (FIG. 3) Effect of compound 1 (DN203368) on the proliferation of normal cells including BJ and CHO cells; (FIG. 4) Effect of Compound 1 (DN203368) on proliferation of colon cancer cells; (FIG. 5) Normalized cell viability (%) of normal cell lines and colon cancer cells after compound 1 (DN203368) treatment; (FIG. 6) Concentration that induces 50% cell growth inhibition (GI ₅₀ ) of colon cancer cells for Compound 1 (DN203368)].
7 and 8 show a comparison of the proliferation inhibitory effects of existing anticancer drugs (oxaliplatin and 5-FU) and compound 1 (DN203368) in colon cancer cells [(FIG. 7) of oxaliplatin and compound 1 (DN203368) in colon cancer cells. antiproliferative effect; (FIG. 8) Proliferation inhibitory effect of 5-FU and Compound 1 (DN203368) in colon cancer cells].
9 and 10 show Compound 1 (DN203368)-mediated cell cycle arrest and induction of apoptosis in colon cancer cells [(Fig. 9) Cell cycle analysis in Compound 1 (DN203368)-treated HCT116, SW480 and RKO cells. graph showing; (FIG. 10) FACS analysis showing the percentage of apoptotic cells].
Figure 11 shows the induction of compound 1 (DN203368)-mediated caspase-3-dependent apoptosis through upregulation of p53 acetylation [(A) Expression level of ERRβ/γ in colon cancer cells after treatment with compound 1 (DN203368) ; (B) Changes in expression of cell cycle related proteins in Compound 1 (DN203368)-treated colon cancer cells; (C) Changes in apoptosis regulatory protein expression in Compound 1 (DN203368)-treated human colon cancer cells; (D) expression levels of ERRβ/γ, cell cycle inhibition regulatory proteins and apoptosis regulatory proteins in compound 1 (DN203368)-treated mouse colon cancer cells; (E) Time-dependent changes in apoptosis-related protein expression in 12 μM Compound 1 (DN203368)-treated HCT-116 cells].
Figure 12 shows the quantification of compound 1 (DN203368)-mediated induction of caspase 3-dependent apoptosis [(A) In vitro bioluminescence of time-dependent caspase-3 activation in compound 1 (DN203368)-treated colon cancer cells. signal quantification; (B) time-dependent cell viability in Compound 1 (DN203368)-treated colon cancer cells; (C) normalized caspase-3 activation in Compound 1 (DN203368)-treated colon cancer cells; (D) Inhibition of caspase-3 activation by Z-VAD treatment in compound 1 (DN203368)-treated HCT-116 cells (Z-VAD: pan-caspase inhibitor), caspase-3 activity shows viability CCK8 standardized with respect to the results of the assay].
Figure 13 shows the anti-tumor effect of compound 1 (DN203368) on colorectal cancer progression [(A) Schematic for in vivo treatment of HCT-116 xenograft mice. HCT-116 tumor-bearing mice were randomly divided into three groups: group 1: vehicle, group 2: 5 mg/kg compound 1 (DN203368), and group 3: 10 mg/kg compound 1 (DN203368), and compound 1 (DN203368) was administered to mice via intraperitoneal injection once daily for 10 days; (B and C) Relative tumor volume in HCT-116 tumor-bearing mice. Compound 1 (DN203368) was dose-dependently administered to mice via intraperitoneal injection. RTV=(tumor volume on day of measurement)/(tumor volume on day 0); (D) Body weight measurement of HCT-116 tumor-bearing mice; (E) Serum biochemical analysis of vehicle-treated and Compound 1 (DN203368)-treated mice].
Figure 14 shows the antitumor effect of Compound 1 (DN203368) on SW480 and RKO xenograft models of colorectal cancer [(A) Schematic for in vivo treatment in RKO and SW480 colorectal cancer models. Tumor-bearing mice were randomly divided into two groups: Group 1: vehicle and Group 2: 10 mg/kg Compound 1 (DN203368), and Compound 1 (DN203368) was administered to the mice via intraperitoneal injection once a day for 10 days. box; (B and C) Relative tumor volumes of SW480 and RKO xenograft mice after treatment with compound 1 (DN203368) via intraperitoneal injection. RTV=(tumor volume on day of measurement)/(tumor volume on day 0); (D and E) body weight measurements of SW480 or RKO tumor-bearing mice; (F) Immunohistochemical staining with anti-cleaved caspase-3 and Ki-67 antibodies in compound 1 (DN203368)-treated SW480 tumor tissue; (G) Immunohistochemical staining with anti-cleaved caspase-3 in Compound 1 (DN203368)-treated RKO tumor tissue].
Figure 15 shows the induction of potent antitumor effects after oral administration of Compound 1 (DN203368) in a colorectal cancer model [(A) Schematic for in vivo treatment in HCT-116 and CT26 xenograft models. Tumor-bearing mice were randomly divided into two groups: Group 1: vehicle and Group 2: 10 mg/kg Compound 1 (DN203368), and Compound 1 (DN203368) was administered to the mice via oral administration once a day for 10 days. ; (B) Relative tumor volume in the HCT-116 xenograft model after oral administration of compound 1 (DN203368). RTV=(tumor volume on day of measurement)/(tumor volume on day 0); (C) Body weight measurement of HCT-116 tumor-bearing mice; (D) Evaluation of tumor volume in the CT26 xenograft model following oral administration of Compound 1 (DN203368); (E) Weight measurement of CT26 tumor-bearing mice].
16 shows serum biochemical analysis in CT26 tumor-bearing mice after oral administration of compound 1 (DN203368).
Figure 17 shows the inhibition of proliferation of Compound 1 (DN203368)-treated prostate cancer, ovarian cancer, breast cancer, neuroblastoma, undifferentiated and dedifferentiated thyroid cancer cells [(A) normal cells after treatment with Compound 1 (DN203368), prostate cancer, normalized cell viability (%) of ovarian cancer, breast cancer, and neuroblastoma; (B) Normalized cell viability (%) of undifferentiated and dedifferentiated thyroid carcinoma cells after compound 1 (DN203368) treatment].
Figure 18 shows the antitumor effect of Compound 1 (DN203368) on neuroblastoma and ovarian cancer models [(A) Relative tumor volume of BE2C xenograft mice treated with Compound 1 (DN203368) via intraperitoneal injection; (B) Relative tumor volume of A2780 xenograft mice after treatment with compound 1 (DN203368) via intraperitoneal injection].
Figure 19 shows the antitumor effect of Compound 1 (DN203368) on a breast cancer model [(A) tumor volume of MDA-MB231 xenograft mice after treatment with Compound 1 (DN203368) via intraperitoneal injection; (B) Tumor volume of MDA-MB231 orthotopic mice after treatment with compound 1 (DN203368) via intraperitoneal injection].
Figure 20 shows the antitumor effect of Compound 1 (DN203368) on a dedifferentiated thyroid carcinoma BHP103scp model [(A) Relative tumor volume of BHP103scp xenograft mice treated with Compound 1 (DN203368) via intraperitoneal injection; (B) Body weight measurement of BHP103scp tumor-bearing mice; (C) Immunohistochemical staining with anti-cleaved caspase-3 and Ki-67 antibodies in compound 1 (DN203368)-treated BHP103scp tumor tissue].
Figure 21 shows the inhibition of proliferation of Compound 12 (DN3317)-treated prostate cancer, ovarian cancer, glioblastoma and dedifferentiated thyroid cancer cells [normal cell lines after treatment with Compound 12 (DN3317) and prostate, ovarian cancer, glioblastoma and dedifferentiation Normalized cell viability (%) of thyroid cancer cells].
22 to 24 are normalized cell viability (%) of colorectal cancer cells according to the combined administration of compound 1 (DN203368) and conventional anticancer drugs.

Hereinafter, the present invention will be described in more detail. At this time, if there is no other definition in the technical terms and scientific terms used, they have meanings commonly understood by those of ordinary skill in the art to which this invention belongs, and will unnecessarily obscure the gist of the present invention in the following description. Descriptions of possible known functions and configurations are omitted.

The following terms used herein are defined as follows, but these are only illustrative and are not intended to limit the present invention, application or use.

The singular form used herein may be intended to include the plural form as well, unless the context dictates otherwise.

The term "comprises" in the present specification is an open description having the same meaning as expressions such as "comprises", "includes", "has" or "characterized by", and elements not additionally listed, etc. does not rule out

As used herein, the terms "substituent", "radical", "group", "moiety", and "fragment" may be used interchangeably.

As used herein, the term "C _A -C _B " means "more than A and less than B", and the term "A to B" means "more than A and less than B".

As used herein, the term "alkyl" refers to a monovalent straight-chain or branched saturated hydrocarbon radical composed only of carbon and hydrogen atoms. The alkyl may have 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 7 carbon atoms. Examples of the alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, ethylhexyl, and the like.

As used herein, the term "cycloalkyl" refers to a monovalent saturated carbocyclic radical composed of one or more rings. Examples of cycloalkyl radicals include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

As used herein, the term "alkoxy" refers to an -O-alkyl radical, where 'alkyl' is as defined above. Specific examples include, but are not limited to, methoxy, ethoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, and the like.

As used herein, the term "alkylthio" refers to an -S-alkyl radical, where 'alkyl' is as defined above. Specific examples include, but are not limited to, methylthio, ethylthio, isopropylthio, butylthio, isobutylthio, t-butylthio, and the like.

As used herein, the term "halo" or "halogen" refers to a halogen group element and includes, for example, fluoro, chloro, bromo and iodo.

As used herein, the term "haloalkyl", "haloalkoxy" or "haloalkylthio" refers to an alkyl, alkoxy or alkylthio group in which one or more hydrogen atoms are substituted with halogen atoms, respectively, wherein alkyl, alkoxy, alkylthio and Halogen is as defined above. For example, haloalkyl includes fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, perfluoroethyl, etc., and haloalkoxy is fluoromethoxy, difluoromethyl oxy, trifluoromethoxy, fluoroethoxy, difluoroethoxy, perfluoroethoxy and the like, and haloalkylthio is fluoromethylthio, difluoromethylthio, trifluoromethylthio, Fluoroethylthio, difluoroethylthio, perfluoroethylthio, etc. are mentioned.

As used herein, the term "aryl" is an organic radical derived from an aromatic hydrocarbon by the removal of one hydrogen, either singly or fused, each ring containing preferably 4 to 7, preferably 5 or 6, ring atoms. It includes a ring system, and even includes a form in which a plurality of aryls are connected by single bonds. Examples include, but are not limited to, phenyl, naphthyl, biphenyl, terphenyl, anthryl, fluorenyl, and the like.

As used herein, the term "alkylcarbonyl" refers to a -C(=O)alkyl radical, where 'alkyl' is as defined above. Examples of such alkylcarbonyl radicals include, but are not limited to, methylcarbonyl, ethylcarbonyl, isopropylcarbonyl, propylcarbonyl, butylcarbonyl, isobutylcarbonyl, t-butylcarbonyl, and the like.

As used herein, the term "alkylcarbonyloxy" means -OC(=O)alkyl radical, where 'alkyl' is as defined above. Examples of such alkylcarbonyloxy radicals include methylcarbonyloxy, ethylcarbonyloxy, isopropylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, isobutylcarbonyloxy, t-butylcarbonyloxy, and the like. However, it is not limited thereto.

As used herein, "amino" means -NH ₂ , "hydroxy" means -OH, "nitro" means -NO ₂ , and "cyano" means -CN.

As used herein, the term "alkylamino" refers to an amino radical in which one or two alkyls are substituted, and specific examples include methylamino (-NHMe), dimethylamino (-NMe ₂ ), ethylamino (-NHEt), diethylamino (-NEt ₂ ); and the like, but are not limited thereto.

As used herein, the term "pharmaceutically acceptable" means that it exhibits characteristics that are not toxic to objects such as cells or humans exposed to the composition, and is suitable for use as a pharmaceutical preparation, and generally refers to such use. It is considered safe for such use and is officially approved by a national regulatory authority for such use or is listed in the Korean Pharmacopoeia or the United States Pharmacopoeia.

As used herein, the term "pharmaceutically acceptable salt" is a concentration that has a relatively non-toxic and harmless effective effect on patients, and the side effects caused by the salt do not reduce the beneficial effects of the compound itself of the present invention. means any and all organic or inorganic addition salts of a compound.

As used herein, the terms "pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to a substance that aids administration of an active agent and absorption by a subject.

As used herein, the term "prevention" refers to any activity that inhibits or delays the occurrence, spread, and recurrence of cancer.

As used herein, the term "improvement" refers to any activity that at least reduces a parameter related to the condition being treated, for example, the severity of a symptom.

As used herein, the term "treatment" refers to any activity that improves or beneficially changes the symptoms of cancer.

As used herein, the term "individual" refers to all animals, including humans, who have or are likely to develop cancer. The animal may be not only humans but also mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, and cats that require treatment for similar symptoms, but are not limited thereto.

As used herein, the term "administration" means introducing the pharmaceutical composition of the present invention to a subject by any appropriate method, and the administration route of the composition of the present invention is various oral or parenteral routes as long as it can reach the target tissue. can be administered through

As used herein, the term "combined administration" can be achieved by administering the individual components of the therapy simultaneously, sequentially, or separately. Combination treatment effect is obtained by administering two or more drugs simultaneously or sequentially, or by alternately administering them at regular or unspecified intervals. , efficacy measured by time to disease progression or survival can be defined as being therapeutically superior to and capable of providing a synergistic effect over the efficacy obtainable by administering one or the other of the components of the combination therapy at conventional doses. can

As used herein, the term "pharmaceutically effective amount" means an amount that is sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects, and the effective dose level is dependent on the patient's gender, Factors including age, weight, health condition, type and severity of disease, activity of drug, sensitivity to drug, method of administration, time of administration, route of administration, and excretion rate, duration of treatment, combinations or drugs used concurrently, and other medical It can be readily determined by a person skilled in the art according to factors well known in the art.

As used herein, the term "food" means meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcohol Beverages, vitamin complexes, health functional foods and health foods, etc., include all foods in a conventional sense.

As used herein, the term "functional health food" refers to food manufactured and processed using raw materials or ingredients having useful functionalities for the human body according to the Act on Health Functional Foods No. 6727, and "functional" refers to the human body. It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients for the structure and function of food or physiological functions.

As used herein, the term "acceptable food salt" means a formulation of a compound that does not cause serious irritation to the organism to which the compound is administered and does not impair the biological activity and physical properties of the compound.

The present invention provides an ethene compound represented by Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof:

[Formula 1]

In Formula 1,

R ¹ is C1-C20 alkyl or C3-C20 cycloalkyl;

R ² is C1-C20 alkyl, halogen, C3-C20 cycloalkyl, -L ^a1 -R ^a1 , -NR ^a2 R ^a3 , nitro or cyano;

L ^a1 is O or S;

R ^a1 is hydrogen, C1-C20 alkyl, haloC1-C20 alkyl, C3-C20 cycloalkyl, C1-C20 alkoxyC1-C20 alkyl, C1-C20 alkylthioC1-C20 alkyl or C1-C20 alkylcarbonyl;

R ^a2 and R ^a3 are each independently hydrogen, C1-C20 alkyl, C3-C20 cycloalkyl or C6-C20 aryl;

A ¹ to A ⁴ are each independently CR ^a4 or N;

R ^a4 is hydrogen or hydroxy;

R ³ is hydrogen, C1-C20 alkyl or C3-C20 cycloalkyl;

L is CR ^a5 or N;

R ^a5 is hydrogen or C1-C20 alkyl;

m is an integer from 1 to 5, and when m is an integer of 2 or greater, R ₂ may be the same or different;

n is an integer of 0 or 1;

The alkyl of R ₂ and R ³ may be further substituted with one or more selected from the group consisting of halogen, C1-C20 alkyl, C1-C20 alkoxy, hydroxy, amino, mono- or di-C1-C20 alkylamino.

The ethene compound of Chemical Formula 1 according to the present invention is a compound with a novel structure and can be used as an active ingredient for preventing or treating cancer by controlling the expression level of ERRβ/γ, which is overexpressed in cancer cells. That is, the ethene compound according to the present invention acts as an ERRβ/γ inverse agonist and can be useful as a target anticancer agent for cancer.

In addition, the ethene compound of the present invention has high biocompatibility and high selectivity, is orally bioavailable, and can induce apoptosis specifically only for cancer cell lines by acting as an ERRβ/γ inverse agonist without exhibiting toxicity to normal cells. Therefore, it can be usefully used as an effective preventive and therapeutic agent for cancer without side effects. Cancer diseases that can be prevented, treated, or ameliorated by treatment with the ethene compound according to the present invention are intractable cancers, specifically ovarian cancer, prostate cancer, breast cancer, neuroblastoma, glioblastoma, undifferentiated thyroid cancer, dedifferentiated thyroid cancer, or colorectal cancer. etc. may be included.

As a result of measuring the anticancer effect of the ethene compound according to the present invention through in vitro and in vivo experiments, the ethene compound according to the present invention reduces the viability of cancer cells, inhibits proliferation, Since apoptosis of cancer cells is increased, it was confirmed that the anticancer effect was excellent. Therefore, the ethene compound according to the present invention can be usefully used as an active ingredient of a pharmaceutical composition for preventing or treating cancer.

In an embodiment, at least two of A ¹ to A ⁴ may be CR ^a4 , the others may be CR ^a4 or N, and R ^a4 may be hydrogen or hydroxy.

In one embodiment, the ethene compound may be represented by Chemical Formula 2 below.

[Formula 2]

In Formula 2, R ¹ , R ² , R ³ , L, m and n are the same as defined in Formula 1;

A ¹ is CH or N;

a is an integer of 0 or 1;

In one embodiment, R ² is halogen, hydroxy, C1-C20 alkoxy, haloC1-C20 alkoxy, C1-C20 alkoxyC1-C20 alkoxy, C1-C20 alkylthioC1-C20 alkoxy, C1-C20 alkylcarbo yloxy, C1-C20 alkylthio, haloC1-C20 alkylthio, C1-C20 alkylcarbonylthio, -NR ^a2 R ^a3 , nitro or cyano; R ^a2 is hydrogen or C1-C20 alkyl; R ^a3 is C1-C20 alkyl; m may be an integer from 1 to 3.

In a preferred embodiment of the present invention, R ¹ is C1-C10 alkyl or C3-C10 cycloalkyl; R ² is hydroxy, C1-C10 alkoxy, haloC1-C10 alkoxy, C1-C10 alkoxyC1-C10 alkoxy, C1-C10 alkylthioC1-C10 alkoxy, C1-C10 alkylcarbonyloxy, C1-C10 alkylthio, haloC1-C10 alkylthio, C1-C10 alkylcarbonylthio or -NR ^a2 R ^a3 ; R ^a2 is hydrogen or C1-C10 alkyl; R ^a3 is C1-C10 alkyl; R ³ is hydrogen or C1-C10 alkyl; L is CH or N; m is an integer from 1 to 3; n may be an integer of 0 or 1.

In a preferred embodiment of the present invention, R ³ may be C1-C10 alkyl, more preferably branched C3-C7 alkyl, specifically isopropyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, t-pentyl, s-pentyl, 3-pentyl or s-isopentyl.

According to one embodiment, the R ³ may be isopropyl.

The ethene compound according to an embodiment may be specifically represented by Chemical Formula 3, Chemical Formula 4, or Chemical Formula 5 below.

[Formula 3]

[Formula 4]

[Formula 5]

In Formulas 3 to 5,

R ¹ is C1-C10 alkyl or C3-C10 cycloalkyl;

At least one of R ¹¹ , R ¹² and R ¹³ is hydroxy, C1-C10 alkoxy, haloC1-C10 alkoxy, C1-C10 alkoxyC1-C10 alkoxy, C1-C10 alkylcarbonyloxy, C1-C10 alkylthio, halo C1-C10 Alkylthio, C1-C10 Alkylcarbonylthio or diC1-C10 Alkylamino, the rest being hydrogen, hydroxy, C1-C10 Alkoxy, haloC1-C10 Alkoxy, C1-C10 AlkoxyC1-C10 Alkoxy, C1 -C10 alkylcarbonyloxy, C1-C10 alkylthio, haloC1-C10 alkylthio, C1-C10 alkylcarbonylthio or diC1-C10 alkylamino;

a is an integer of 0 or 1;

n is an integer of 0 or 1;

According to one embodiment, in Chemical Formulas 3 to 5, R ¹ is C1-C7 alkyl or C3-C8 cycloalkyl; At least one of R ¹¹ , R ¹² and R ¹³ is hydroxy, C1-C7 alkoxy, C1-C7 alkylcarbonyloxy, C1-C7 alkylthio or diC1-C7 alkylamino, and the others are hydrogen, hydroxy, C1 -C7 alkoxy, C1-C7 alkylcarbonyloxy, C1-C7 alkylthio, or diC1-C7 alkylamino; a is an integer of 0 or 1; n may be an integer of 0 or 1.

Specifically, R ¹¹ is hydrogen; R ¹² is hydrogen, hydroxy, C1-C7 alkoxy, C1-C7 alkylcarbonyloxy, C1-C7 alkylthio or diC1-C7 alkylamino; R ¹³ can be hydroxy, C1-C7 alkoxy, C1-C7 alkylcarbonyloxy, C1-C7 alkylthio or diC1-C7 alkylamino.

Specifically, R ¹¹ is hydroxy or C1-C7 alkoxy; R ¹² is hydrogen; R ¹³ can be hydroxy, C1-C7 alkoxy, C1-C7 alkylcarbonyloxy, C1-C7 alkylthio or diC1-C7 alkylamino.

Specifically, R ¹¹ and R ¹³ are hydrogen; R ¹² can be hydroxy, C1-C7 alkoxy, C1-C7 alkylcarbonyloxy, C1-C7 alkylthio or diC1-C7 alkylamino.

According to one embodiment, in Chemical Formulas 3 to 5, R ¹ may be C2-C5 alkyl or C3-C7 cycloalkyl, preferably C2-C4 alkyl or C3-C6 cycloalkyl.

Specifically, R ¹ is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, t-pentyl, s-pentyl, 3-pentyl, s-iso It may be pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, and more specifically, R ¹ is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

The ethene compound according to an embodiment may be at least one selected from the group of compounds below, but is not limited thereto.

It will be apparent to those skilled in the art that the method for preparing an ethene compound according to an embodiment may be performed using a method known in the art or by appropriately changing it. In addition, the reaction time in the preparation method of Chemical Formula 1 according to an embodiment of the present invention may vary depending on the type and amount of the reactant, solvent, and the reaction after confirming that the starting material is completely consumed through TLC, for example. complete the When the reaction is complete, the solvent may be distilled off under reduced pressure, and then the target product may be separated and purified through a conventional method such as column chromatography. Further details are described in the Examples below.

The present invention includes all of the above ethene compounds, pharmaceutically acceptable salts thereof, or N-oxides thereof, as well as possible prodrugs, hydrates and solvates that can be prepared therefrom.

That is, the ethene compound of the present invention can be used in the form of prodrugs, hydrates, solvates, and pharmaceutically acceptable salts in order to improve absorption or solubility in vivo. and pharmaceutically acceptable salts are also within the scope of the present invention. In addition, since the ethene compound has a chiral carbon, stereoisomers thereof exist, and these stereoisomers are also included within the scope of the present invention.

The ethene compound of the present invention can be used in the form of a pharmaceutically acceptable salt, and the pharmaceutically acceptable salt is a salt prepared according to a conventional method in the art, and the preparation method thereof is known to those skilled in the art. Specifically, the pharmaceutically acceptable salt includes, but is not limited to, pharmacologically or physiologically acceptable salts derived from free acids and bases.

Acid addition salts formed by pharmaceutically acceptable free acids include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid, phosphorous acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, Fluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorb It is obtained from organic acids such as acid, carbonic acid, vanillic acid, and hydroiodic acid. Such pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, Bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succi nate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxy Benzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxy oxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like.

The acid addition salt can be prepared by a conventional method. For example, the ethene compound of the present invention is dissolved in a water-miscible organic solvent such as methanol, ethanol, acetone, dichloromethane, acetonitrile, etc., and an organic or inorganic acid is added to form a precipitate. It may be prepared by filtering and drying, or by distilling the solvent and excess acid under reduced pressure, drying it, and crystallizing it in an organic solvent.

In addition, a pharmaceutically acceptable metal salt may be prepared using a base. The alkali metal salt or alkaline earth metal salt is obtained, for example, by dissolving the ethene compound of the present invention in an excess alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved ethene compound salt, and then evaporating and drying the filtrate. At this time, as the metal salt, it is pharmaceutically suitable to prepare a sodium, potassium, or calcium salt, but is not limited thereto. In addition, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (eg, silver nitrate).

The hydrate of the ethene compound of the present invention comprises a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces, or A pharmaceutically acceptable salt thereof is meant.

The solvate of the ethene compound of the present invention refers to the ethene compound of the present invention or a pharmaceutically acceptable salt thereof containing a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Solvents that can be used include those that are volatile and non-toxic.

That is, the ethene compound of the present invention is dissolved in a water-miscible solvent such as methanol, ethanol, acetone, or 1,4-dioxane, and then crystallized or recrystallized after adding a free acid or free base to obtain a solvent containing a hydrate Cargo can be formed. Therefore, the novel compounds of the present invention include stoichiometric solvates including hydrates in addition to compounds containing various amounts of water that can be prepared by methods such as lyophilization.

The ethene compounds of the present invention may have chiral centers and may exist as racemates, racemic mixtures, and individual enantiomers or diastereomers. These isomers can be separated or resolved by conventional methods and any desired isomer can be obtained by conventional synthetic methods or by stereospecific or asymmetric synthesis. All such isomeric forms and mixtures thereof are included within the scope of the present invention.

The ethene compound of the present invention may be administered in the form of a prodrug that is decomposed in the body of a human or animal to provide the ethene compound of the present invention as an active ingredient. Prodrugs can be used to alter and/or improve the physical and/or pharmacokinetic profile of the parent compound and can be formed when the parent compound contains suitable groups or substituents that can be derivatized to form prodrugs.

If any compound (prodrug) is isolated from the body to produce the ethene compound or salt thereof of the present invention, such compound is also included in the scope of the present invention. As used herein and unless otherwise indicated, the term "prodrug" refers to a reaction that is hydrolyzed, oxidized, and subjected to other reactions under biological conditions (ex vivo or in vivo) to provide an active compound, particularly an ethene compound of the present invention. means a compound of the present invention capable of Examples of prodrugs are biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable compounds that are biohydrolyzed to produce the ethene compounds of the present invention, including biohydrolyzable moieties such as ureides, which can be biohydrolyzed, and phosphate analogues which can be biohydrolyzed, but in this specific embodiment is not limited to Preferably, the prodrug of a compound having a carboxylic functional group is a lower alkyl ester of a carboxylic acid. Carboxyl esters are commonly formed by esterifying a portion of a carboxylic acid present in a molecule. Prodrugs can be readily prepared using known methods.

In addition, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the ethene compound of Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof as an active ingredient.

The pharmaceutical composition of the present invention can be used for the purpose of treatment, prevention and alleviation of cancer diseases caused by abnormal cell growth. Cancer diseases that can be prevented, treated, or alleviated by the treatment of the pharmaceutical composition of the present invention may be intractable cancers, specifically ovarian cancer, prostate cancer, breast cancer, neuroblastoma, glioblastoma, undifferentiated thyroid cancer, dedifferentiated thyroid cancer, colon cancer, etc. can

According to one embodiment, as a result of confirming the difference in ERRβ / γ protein expression in human colon cancer and normal colon tissue, a higher level of ERRβ / γ expression was observed in colon cancer tissue than in normal tissue, and the treatment of the ethene compound The proliferation of cancer cells was inhibited by the suppression of ERRβ/γ in colon cancer tissues. Accordingly, the ethene compound according to the present invention may be useful for treating or preventing various cancer diseases by inhibiting the proliferation of cancer cells by controlling the expression level of ERRβ/γ in cancer tissues such as colorectal cancer.

The pharmaceutical composition according to an embodiment further includes a conventional non-toxic pharmaceutically acceptable carrier and/or excipient in addition to the active ingredient, and is a conventional preparation in the pharmaceutical field, that is, a preparation for oral administration or a preparation for parenteral administration. It can be formulated as In addition, diluents such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants may be further included.

Examples of the pharmaceutically acceptable carrier, excipient or diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil, but is not limited thereto.

The pharmaceutical composition of the present invention can be formulated in various forms such as oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and injections of sterile injection solutions according to conventional methods according to the purpose of use. It can be formulated and used, and can be administered through various routes including oral administration or intravenous, intraperitoneal, subcutaneous, rectal, topical administration, and the like.

The formulation for oral administration may optionally be enteric coated, and may exhibit a delayed or sustained release through the enteric coating. That is, the preparation for oral administration may be a dosage form having an immediate or modified release pattern.

The formulation for parenteral administration may be a formulation having an immediate or modified release pattern, and the modified release pattern may be a delayed or sustained release pattern.

In addition, the pharmaceutical composition of the present invention may further include fillers, anti-coagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, and the like.

Formulations for oral administration include, for example, tablets, pills, hard/soft capsules, solutions, suspensions, emulsifiers, syrups, granules, elixirs, etc. These formulations are commonly used fillers in addition to the above active ingredients One or more diluents or excipients such as extenders, wetting agents, disintegrants, lubricants, binders, and surfactants may be used. As the disintegrant, agar, starch, alginic acid or sodium salt thereof, calcium monohydrogen phosphate anhydrous salt, etc. may be used, and as the lubricant, silica, talc, stearic acid or magnesium salt or calcium salt thereof, polyethylene glycol, etc. may be used. , Magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low-substituted hydroxypropyl cellulose and the like may be used as the binder. In addition, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, etc. may be used as diluents, and in some cases, generally known boiling mixtures, absorbents, coloring agents, flavoring agents, sweetening agents, etc. may be used together.

Examples of preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerol, gelatin, etc. may be used. Meanwhile, conventional additives such as solubilizers, tonicity agents, suspending agents, emulsifiers, stabilizers, and preservatives may be included in the injection. In order to formulate an injection, the active ingredient may be mixed in water with a stabilizer or buffer to prepare a solution or suspension, which may be prepared in unit dosage form in an ampoule or vial.

The pharmaceutical composition of the present invention may be sterilized or may further contain adjuvants such as preservatives, stabilizers, thickeners, hydration agents or emulsifiers, salts and/or buffers for adjusting osmotic pressure, and other therapeutically useful substances. It may further contain, and may be formulated according to conventional methods such as dissolution, dispersion, mixing, granulation, gelation or coating.

The pharmaceutically effective amount of the ethene compound, which is an active ingredient in the pharmaceutical composition of the present invention, depends on the patient's health condition, disease type, severity, drug activity, drug sensitivity, administration method, administration time, administration route, and excretion rate. , duration of treatment, factors including medications used in combination or co-administration, and other factors well known in the medical arts. Specifically, the effective amount of the ethene compound in the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, and body weight, and is generally about 0.001 to 500 mg/kg/day, preferably 0.01 to 100 mg. /kg/day, it can be administered daily or every other day or divided into once to several times a day. However, since it may increase or decrease depending on the route of administration, severity of disease, sex, weight, age, etc., the dosage is not limited to the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered orally or parenterally, and the ethene compound according to the present invention enters the gastrointestinal tract by oral administration as an anticancer agent for oral administration to treat cancer, or, for example, It can be absorbed directly from the mouth into the bloodstream, such as by buccal or sublingual administration.

In addition, the present invention relates to an ethene compound of Formula 1, a pharmaceutically acceptable salt thereof, or an N-oxide thereof; And it provides a combination preparation for preventing or treating cancer containing an anticancer agent.

The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by those skilled in the art.

At this time, the other therapeutic agent may mean a known anticancer agent.

The "anti-cancer agent" refers to known drugs used in conventional cancer treatment that exhibit cytotoxicity or growth inhibitory effects on cancer cells by acting on various metabolic pathways of cancer cells. It may include both cytotoxic anticancer agents and targeted anticancer agents.

Cytotoxic anticancer agents refer to anticancer agents that inhibit the synthesis and division of DNA or RNA by intervening in the metabolic pathway of cancer cells, or induce cell death by damaging DNA itself. ), plant-derived alkaloids, topoisomerase inhibitors, alkylating agents, antineoplastic antibiotics, hormones and other drugs.

The topoisomerase inhibitor is a substance that exhibits an anticancer effect by interfering with the action of topoisomerase, an enzyme that regulates the double helix structure of DNA, for example, etoposide, epipodophyllotoxin ) or a combination thereof, but is not limited thereto.

The metabolic antagonist refers to a substance that inhibits the growth and proliferation of cells by antagonizing with an indispensable metabolite for the metabolism or growth of microorganisms or tumor cells. The antimetabolite is, for example, metotrexate, pemetrexed, cladribine, fludarabine, mercaptopurine, 6-thioguanine , clofarabine, 5-azacytidine, cytarabine, decitabine, enocitabine, gimeracil, oteracil ), capecitabine, camofur, doxifluridine, gemcitabine, tegafur, 5-fluorouracil, or combinations thereof It may be, but is not limited thereto.

The plant-derived alkaloid refers to an organic compound containing basic nitrogen having a specific and strong physiological action on animals among plant extracts. The plant-derived alkaloids are, for example, etoposide, docetaxel, paclitaxel, cabazitaxel, vinblastine, vincristine, vinorelbine , teniposide, trabectedin, or a combination thereof, but is not limited thereto.

The alkylating agent is a very reactive substance having the ability to introduce an alkyl group R-CH2 into a certain compound, and when applied to cells, it transforms the DNA structure and causes chain scission to exhibit anticancer and cytotoxic effects, Also called DNA-damaging agents. The alkylating agent is, for example, oxaliplatin, bendamustine, chlorambucil, melphalan, busulfan, cyclophosphamide, ifosfamide ( ifosfamide, carmustine, lomustine, nimustine, ranimustine, dacarbaxine, temozolomide, thiotepa, or combinations thereof It may be, but is not limited thereto.

The anticancer antibiotic refers to an antibiotic that inhibits the proliferation of animal tumor cells and shows a life-sustaining effect on cancer-bearing animals. The antitumor antibiotics include, for example, doxorubicin, dactinomycin, daunorubicin, epirubicin, idarubicin, mitoxanthrone, It may be pirarubicin, bleomycin, ixabepilone, mitomycin C, or a combination thereof, but is not limited thereto.

The hormonal agents are meant to regulate, reduce, block or suppress hormonal effects that can promote cancer growth. The hormonal agent is diethylstilbestrol, medroxyprogesterone, megesterol, fulvestrant, tamoxifen, toremifene, bicalutamide ), flutamide, anastrozole, exemestane, letrozole, buserelin, gosereline, leuprorelin, trypto It may be relin (triptorelin), aminoglutethimide (aminoglutethimide) or a combination thereof, but is not limited thereto.

Targeted anticancer agents refer to drugs that selectively attack only cancer cells by targeting proteins of specific parts of cancer cells different from normal cells, and include at least one selected from signal transduction pathway inhibitors, angiogenesis inhibitors, etc. can

Anticancer agents according to one embodiment, Afatinib, oxaliplatin, doxorubicin, paclitaxel, vincristine, daunorubicin, vinblastine, actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, Gleevec (STI-571), Cisplatin, 5-fluorouracil (5-FU), Adriamycin, metotrexate, busulfan, chlorambucil, cyclophosphamide ), melphalan, nitrogen mustard, and nitrosourea.

In one embodiment, the anticancer agent may be at least one selected from afatinib, oxaliplatin, and 5-fluorouracil (5-FU).

The combination preparation according to the present invention can exhibit a remarkable synergistic effect by using the two components together, compared to the treatment effect of each component alone, for the treatment of cancer, prolonging the duration of the drug effect, extending the drug administration interval, or It is possible to reduce the total dose or number of administrations, and as a result, the survival rate and survival period of cancer patients can be extended and side effects can be significantly reduced. In particular, the combination preparation of the present invention can exhibit significantly superior effects in preventing or treating cancer compared to conventional anticancer drug administration alone, and can more effectively inhibit, delay, or stop tumor growth without side effects.

Therefore, the ethene compound according to the present invention, its pharmaceutically acceptable salt or its N-oxide not only exhibits an excellent anticancer effect when used alone, but also exhibits a higher synergistic effect when used in combination with an existing anticancer agent. there is.

In addition, the present invention comprises the step of administering the ethene compound, its pharmaceutically acceptable salt or its N-oxide, or the pharmaceutical composition, or the combination preparation to a subject who has or is at risk of developing cancer. A method for preventing or treating cancer is provided.

In addition, the present invention provides a health functional food composition for preventing or improving cancer, comprising the ethene compound of Formula 1, a food-acceptable salt thereof, or an N-oxide thereof as an active ingredient.

The food chemically acceptable salt is obtained by dissolving the ethene compound of the present invention into inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, sulfonic acids such as methanesulfonic acid, ethanesulfonic acid and p-toluenesulfonic acid, tartaric acid, formic acid, citric acid, It can be obtained by reaction with an organic carbonic acid such as acetic acid, trichloroacetic acid, trifluoroacetic acid, capric acid, isobutanoic acid, malonic acid, succinic acid, phthalic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid and the like. In addition, by reacting the compound of the present invention with a base, salts such as alkali metal salts such as ammonium salts, sodium or potassium salts, alkaline earth metal salts such as calcium or magnesium salts, dicyclohexylamine, N-methyl-D-glucamine , It may also be obtained by forming salts of organic bases such as tris (hydroxymethyl) methylamine, and amino acid salts such as arginine and lysine, but is not limited thereto.

The health functional food composition may be provided in the form of powder, granule, tablet, capsule, syrup or beverage, and the health functional food is used with other foods or food additives in addition to the ethene compound as an active ingredient, can be used appropriately. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use thereof, for example, prevention, health or therapeutic treatment.

The health functional food composition includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts , organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination.

In addition, the health functional food may additionally contain food additives, and the suitability as a 'food additive' is determined according to the general rules of the Food Additive Code and general test methods approved by the Korea Food and Drug Administration unless otherwise specified. It is judged according to standards and standards.

Examples of items listed in the 'Food Additive Code' include chemical synthetic products such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as dark pigment, licorice extract, crystalline cellulose, and guar gum, sodium L-glutamate Mixed formulations such as formulations, noodle-added alkalis, preservatives, and tar colorants may be mentioned.

The ethene compound contained in the health functional food composition can be used according to the effective dose of the pharmaceutical composition, but in the case of long-term intake for the purpose of health and hygiene or health control, it may be less than the above range. And, of course, the active ingredient can be used in an amount greater than the above range because there is no problem in terms of safety.

The health functional food composition is meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes It can be formulated into various formulations such as the like.

In addition, the present invention provides the ethene compound, a pharmaceutically acceptable salt thereof, or an N-oxide thereof for use in the treatment of cancer.

In addition, the present invention provides the use of the ethene compound, its pharmaceutically acceptable salt or its N-oxide for use in the manufacture of a medicament for the treatment of cancer.

Hereinafter, the present invention will be described in more detail through preferred embodiments and experimental examples. However, this is presented as an example of the present invention, and the scope of the present invention is not limited thereto in any sense, and the scope of the present invention is only defined according to the claims to be described later.

[Example 1] (E)-3-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenol ( 1, DN203368 ) manufacture of

Step 1: (E)-3-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl pivalate (b-1) manufacture of

1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine (1.98 g, 6.0 mmol), compound a-1 (1.22 g , 5.0 mmol) and iodobenzene (0.67 mL, 6.0 mmol) were dissolved in a mixed solvent of DMF (80 mL) and water (40 mL), and then 0.025 M PdCl ₂ (PhCN) ₂ (2 mL, 0.05 mmol) was added. It was added and heated at 45° C. for 10 minutes. After adding Cs ₂ CO ₃ (1.96 g, 6.0 mmol), the mixture was heated at 45°C for 12 hours. When the reaction was completed, brine and ethyl acetate were additionally added to the reaction mixture to extract an organic layer. The organic layer was dried over anhydrous Na ₂ SO ₄ and filtered. The residue obtained by distilling the solvent under reduced pressure was purified using column chromatography to obtain 1.18 g (45%) of the target compound b-1.

Step 2: (E)-3-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenol ( One ) manufacture of

After adding compound b-1 (0.33 g, 0.62 mmol) to MeOH:CH ₂ Cl ₂ (6 mL:1 mL) and adding K ₂ CO ₃ (0.086 g, 0.62 mmol), the mixture was stirred at room temperature for 3 hours. Water and ethyl acetate were further added to the reaction mixture to extract an organic layer. The organic layer was dried over anhydrous Na ₂ SO ₄ and filtered. The residue obtained by distilling the solvent under reduced pressure was purified by column chromatography to obtain 0.083 g (30%) of target compound 1 .

¹ H NMR (400 MHz, CD ₃ OD) δ 7.22-7.15 (m, 4H), 7.14-7.08 (m, 4H), 6.87 (d, J = 8.7 Hz, 2H), 6.75 (d, J = 7.5 Hz , 1H), 6.73–6.69 (m, 2H), 6.65 (d, J = 8.8 Hz, 2H), 3.73 (d, J = 13.9 Hz, 3H), 3.60–3.46 (m, 4H), 3.20 (t, J = 11.0 Hz, 3H), 3.09–3.00 (m, 2H), 2.91 (t, J = 12.8 Hz, 3H), 1.39 (d, J = 6.6 Hz, 6H), 0.95 (d, J = 6.9 Hz, 6H); ¹³ C NMR (100 MHz, MEOD) Δ 157.02, 147.04, 145.18, 144.44, 139.59, 138.52, 135.90, 130.63, 130.61, 128.83 15.66; MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₇ N ₂ O [M+H] ⁺ 441.29; found 441.38.

[Example 2] Preparation of (E)-3-(2-cyclopropyl-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylvinyl)phenol ( 2 )

Step 1: Preparation of (E)-3-(2-cyclopropyl-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylvinyl)phenyl pivalate (b-2)

42 mg (31%) of the target compound b-2 was obtained in the same manner as in Step 1 of Example 1, except that compound a-2 was used instead of compound a-1.

Step 2: (E)-3-(2-cyclopropyl-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylvinyl)phenol ( 2 ) manufacture of

8 mg (3%) of the target compound 2 was obtained in the same manner as in Step 2 of Example 1, except that compound b-2 was used instead of compound b-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.15 (dd, J = 12.5, 7.6 Hz, 3H), 7.08 (t, J = 7.3 Hz, 1H), 7.01 (d, J = 6.9 Hz, 2H), 6.84 (d, J = 7.6 Hz, 1H), 6.79 (s, 1H), 6.73 (d, J = 8.7 Hz, 2H), 6.68 (dd, J = 8.0, 1.8 Hz, 1H), 6.58 (d, J = 8.7 Hz, 2H), 3.03 (t, J = 4.7 Hz, 4H), 2.69–2.62 (m, 5H), 1.79 (m, 1H), 1.08 (d, J = 6.5 Hz, 6H), 0.59 (dt , J = 5.9, 4.2 Hz, 2H), 0.28 (q, J = 5.7 Hz, 2H); MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₅ N ₂ O [M+H] ⁺ 439.28; found 439.25.

[Example 3] (E)-1-isopropyl-4-(4-(1-(3-methoxyphenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl)piperazine ( 3 ) manufacturing

After compound 1 (23 mg, 0.052 mmol) was added to DMF (1 mL), iodomethane (7.8 μL, 0.125 mmol) and K ₂ CO ₃ (22 mg, 0.157 mmol) were added, the mixture was stirred at room temperature for 1 hour. Water and ethyl acetate were further added to the reaction mixture to extract an organic layer. The organic layer was dried over anhydrous Na ₂ SO ₄ and filtered. The residue obtained by distilling the solvent under reduced pressure was purified using column chromatography to obtain 3 mg (13%) of the target compound 3 .

¹ H NMR (400 MHz, CD ₃ OD) δ 7.28 (t, J = 7.9 Hz, 1H), 7.18-7.14 (m, 2H), 7.11-7.08 (m, 3H), 6.88-6.82 (m, 4H) , 6.78 (q, J = 1.1 Hz, 1H), 6.67–6.64 (m, 2H), 3.79 (s, 3H), 3.71 (d, J = 13.0 Hz, 2H), 3.57–3.46 (m, 3H), 3.28–3.15 (m, 2H), 3.02–2.92 (m, 3H), 1.40 (dd, J = 17.0, 6.6 Hz, 6H), 0.93 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₉ N ₂ O [M+H] ⁺ 455.31; found 455.30.

[Example 4] (E)-3-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl acetate ( 4 ) manufacture of

Compound 1 (5 mg, 0.011 mmol) was added to THF:pyridine (2 mL:1 mL), and acetic anhydride (2.6 μL, 0.027 mmol) was added thereto, followed by heating at 60°C for 12 hours. Water and ethyl acetate were further added to the reaction mixture to extract an organic layer. The organic layer was dried over anhydrous Na ₂ SO ₄ and filtered. The residue obtained by distilling the solvent under reduced pressure was purified using column chromatography to obtain 1.8 mg (26%) of the target compound 4 .

¹ H NMR (400 MHz, CD ₃ OD) δ 7.18-7.00 (m, 7H), 6.86 (d, J = 8.2 Hz, 2H), 6.74-6.64 (m, 4H), 3.71 (d, J = 13.3 Hz , 2H), 3.50 (d, J = 13.0 Hz, 3H), 3.19 (t, J = 11.6 Hz, 2H), 3.05–2.90 (m, 3H), 2.28 (s, 1H), 1.37 (d, J = 7.1 Hz, 6H), 1.29 (s, 3H), 0.93 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₂ H ₃₉ N ₂ O ₂ [M+H] ⁺ 483.30; found 483.04.

[Example 5] (E) -4- (1- (4- (4-isopropylpiperazin-1-yl) phenyl) -3-methyl-2-phenylbut-1-en-1-yl) phenol ( 12, DN3317 ) manufacture of

Step 1: (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl pivalate (b-3) manufacture of

0.99 g (38%) of the target compound b-3 was obtained in the same manner as in Step 1 of Example 1, except that compound a-3 was used instead of compound a-1.

Step 2: (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenol ( 12 ) manufacture of

0.31 g (12%) of the target compound 12 was obtained in the same manner as in Step 2 of Example 1, except that compound b-3 was used instead of compound b-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.18-7.15 (m, 2H), 7.12-7.06 (m, 5H), 6.90 (d, J = 8.7 Hz, 2H), 6.79 (d, J = 8.5 Hz , 2H), 6.76 (d, J = 8.8 Hz, 2H), 3.73 (d, J = 13.2 Hz, 3H), 3.27 (d, J = 11.3 Hz, 2H), 3.15–3.05 (m, 3H), 1.40 (d, J = 6.6 Hz, 6H), 0.94 (d, J = 6.8 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₇ N ₂ O [M+H] ⁺ 441.29; found 441.17.

[Example 6] Preparation of (E) -4-(2-cyclopropyl-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylvinyl)phenol ( 13 )

Step 1: Preparation of (E)-4-(2-cyclopropyl-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylvinyl)phenyl pivalate (b-4)

0.18 g (45%) of target compound b-4 was obtained in the same manner as in step 1 of Example 1, except that compound a-4 was used instead of compound a-1.

Step 2: (E)-4-(2-cyclopropyl-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylvinyl)phenol ( 13 ) manufacture of

5.2 mg (31%) of target compound 13 was obtained in the same manner as in step 2 of Example 1, except that compound b-4 was used instead of compound b-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.32 (d, J = 8.7 Hz, 1H), 7.17-7.10 (m, 3H), 7.06 (m, 2H), 7.02-6.98 (m, 2H), 6.83 -6.75 (m, 2H), 6.69-6.62 (m, 2H), 6.40-6.32 (m, 1H), 3.91 (d, J = 9.3 Hz, 1H), 3.73 (d, J = 13.4 Hz, 1H), 3.64-3.50 (m, 3H), 3.26-3.12 (m, 2H), 3.01 (t, J = 12.0 Hz, 1H), 1.85-1.72 (m, 1H), 1.43 (d, J = 6.6 Hz, 3H) , 1.38 (d, J = 6.7 Hz, 3H), 0.61–0.56 (m, 2H), 0.32–0.25 (m, 2H); MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₅ N ₂ O [M+H] ⁺ 439.28; found 439.13.

[Example 7] (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3,3-dimethyl-2-phenylbut-1-en-1-yl)phenol ( 14 ) manufacture of

Step 1: (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3,3-dimethyl-2-phenylbut-1-en-1-yl)phenyl pivalate (b- 5) Manufacture of

9 mg (7%) of the target compound b-5 was obtained in the same manner as in Step 1 of Example 1, except that compound a-5 was used instead of compound a-1.

Step 2: (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3,3-dimethyl-2-phenylbut-1-en-1-yl)phenol ( 14 ) manufacture of

1 mg (21%, E/Z=1:1) of target compound 14 was obtained in the same manner as in Step 2 of Example 1, except that compound b-5 was used instead of compound b-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.26 (d, J = 8.5 Hz, 1H), 7.15-7.10 (m, 1H), 7.08-7.01 (m, 4H), 7.00-6.91 (m, 2H) , 6.91–6.84 (m, 1H), 6.79–6.69 (m, 2H), 6.59 (d, J = 8.8 Hz, 1H), 6.31 (d, J = 8.6 Hz, 1H), 3.87 (d, J = 13.9 Hz, 1H), 3.66-3.44 (m, 4H), 3.18-3.11 (m, 2H), 3.02 (t, J = 13.0 Hz, 1H), 2.86-2.79 (m, 1H), 1.36 (q, J = 6.4, 5.9 Hz, 6H), 1.01–0.88 (m, 9H). MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₉ N ₂ O [M+H] ⁺ 455.31; found 455.31.

[Example 8] (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl acetate ( 15 ) manufacture of

1.7 mg (31%) of target compound 15 was obtained in the same manner as in Example 4, except that compound 12 was used instead of compound 1.

MS (ESI ⁺ ) m/z calcd for C ₃₂ H ₃₉ N ₂ O ₂ [M+H] ⁺ 483.30; found 483.02.

[Example 9] (E,Z)-1-isopropyl-4-(4-(1-(4-methoxyphenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl)piperazine ( 16 ) manufacture of

3 mg of the target compound 16 (13%, E/Z=8:1) was obtained in the same manner as in Step 1 of Example 1, except that compound a-6 was used instead of compound a-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.24-7.14 (m, 4H), 7.11-7.03 (m, 4H), 6.96-6.89 (m, 1H), 6.83-6.78 (m, 2H), 6.51 ( d, 2H), 3.97-3.88 (m, 2H), 3.84-3.79 (m, 1H), 3.63 (s, 3H), 3.62-3.57 (m, 2H), 3.16-2.96 (m, 4H), 2.08- 1.99 (m, 1H), 1.45 (d, J = 6.7 Hz, 6H), 0.95 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₉ N ₂ 0 [M+H] ⁺ 455.31; found 455.12.

[Example 10] (E,Z)-5-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)-2- Preparation of methoxyphenol ( 5 )

8 mg of the target compound 5 (8%, E/Z=6:1) was obtained in the same manner as in Step 1 of Example 1, except that compound a-7 was used instead of compound a-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.16-7.02 (m, 2H), 7.02-6.92 (m, 3H), 6.85-6.75 (m, 3H), 6.69-6.21 (m, 4H), 3.76 ( s, 3H), 3.66-3.58 (m, 2H), 3.48-3.38 (m, 3H), 3.20-3.10 (m, 2H), 3.08-2.93 (m, 3H), 1.36-1.25 (m, 6H), 0.86-0.80 (m, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₈ N ₂ O [M+H] ⁺ 471.30; found 471.25.

[Example 11] (E)-1-(4-(1-(3,5-dimethoxyphenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl)-4-isopropylpiperazine ( 6 ) manufacture of

16 mg (6%) of target compound 6 was obtained in the same manner as in step 1 of Example 1, except that compound a-8 was used instead of compound a-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.07 (m, 2H), 7.03-6.95 (m, 3H), 6.80-6.74 (m, 2H), 6.57-6.50 (m, 2H), 6.31-6.29 ( m, 3H), 3.67 (s, 6H), 3.66-3.57 (m, 2H), 3.46-3.35 (m, 3H), 3.08 (t, J = 11.2 Hz, 2H), 2.96-2.85 (m, 1H) , 2.77 (t, J = 12.1 Hz, 2H), 1.26 (d, J = 6.7 Hz, 6H), 0.84 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₂ H ₄₁ N ₂ O ₂ [M+H] ⁺ 485.32; found 485.38.

[Example 12] (E)-3-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)-5-methoxyphenol ( 7 ) Manufacture of

After putting Compound 6 (12 mg, 0.025 mmol) in dichloromethane (1 mL) and lowering the temperature to 0 °C, 1M BBr ₃ (74 μL, 0.074 mmol) was slowly added. The temperature was raised to room temperature and stirred for 1 hour. The residue obtained by distilling the reaction solution under reduced pressure was purified using column chromatography to obtain 1 mg of the target compound 7 (8%, E/Z = 7:1).

¹ H NMR (400 MHz, CD ₃ OD) δ 7.18-7.14 (m, 2H), 7.11-7.05 (m, 3H), 6.87 (d, J = 8.7 Hz, 2H), 6.63 (d, J = 8.7 Hz , 2H), 6.32-6.26 (m, 3H), 3.75 (s, 3H), 3.71 (d, J = 13.4 Hz, 2H), 3.50-3.47 (m, 3H), 3.21-3.15 (m, 2H), 3.08–3.01 (m, 1H), 2.87 (t, J = 12.6 Hz, 2H), 1.37 (d, J = 6.6 Hz, 6H), 0.94 (dd, J = 6.9, 2.4 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₉ N ₂ O ₂ [M+H] ⁺ 471.30; found 471.34.

[Example 13] (E)-5-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)benzene-1,3 Preparation of -diol ( 8 )

In the same manner as in Example 12, 1 mg (4%) of the target compound 8 was obtained.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.19-7.16 (m, 2H), 7.13-7.07 (m, 3H), 6.88 (d, J = 8.8 Hz, 2H), 6.65 (d, J = 8.8 Hz , 2H), 6.23–6.20 (m, 3H), 3.73 (m, 2H), 3.56–3.49 (m, 3H), 3.23–3.09 (m, 3H), 2.89 (t, J = 11.8 Hz, 2H), 1.39 (d, J = 6.6 Hz, 6H), 0.96 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₇ N ₂ O ₂ [M+H] ⁺ 457.29; found 457.33.

[Example 14] (E) -4- (4- (1- (3-hydroxyphenyl) -3-methyl-2-phenylbut-1-en-1-yl) phenyl) -1-isopropylpiperazine 1-oxide ( 27 ) manufacture of

Compound 1 (13 mg, 0.030 mmol) was added to DCM (2 mL), and mCPBA (3 mg, 0.015 mmol) was added thereto, followed by stirring at room temperature for 10 minutes. An aqueous solution of NaHSO ₄ was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous Na ₂ SO ₄ and filtered. The residue obtained by distilling the solvent under reduced pressure was purified by column chromatography to obtain 2 mg (16%) of the target compound 27 .

¹ H NMR (400 MHz, CD ₃ OD) δ 7.55 (d, J = 8.9 Hz, 2H), 7.13-7.04 (m, 5H), 7.02-6.98 (m, 3H), 6.68 (d, J = 7.6 Hz , 1H), 6.63–6.59 (m, 12), 4.39 (t, J = 11.6 Hz, 2H), 4.06 (t, J = 11.6 Hz, 2H), 3.59–3.51 (m, 1H), 3.13 (t, J = 13.8 Hz, 4H), 3.01–2.92 (m, 1H), 1.32 (d, J = 6.5 Hz, 6H), 0.85 (d, J = 6.9 Hz, 6H); ¹³ C NMR (100 MHz, MEOD) Δ 157.31, 149.93, 147.30, 144.87, 143.26, 138.66, 137.59, 130.82, 130.46, 129.17, 127.00, 126.00, 119.95, 118.67, 115.64, 113.50 31.68, 20.51, 14.95; MS (ESI ⁺ ) m/z calculated for C ₃₀ H ₃₇ N ₂ O ₂ [M+H] ⁺ 456.29; found 456.32.

[Example 15] (E)-3,3'-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methylbut-1-ene-1,2-diyl)diphenol ( 9 ) manufacture of

Step 1: (E)-3-(2-(3-hydroxyphenyl)-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methylbut-1-en-1-yl)phenyl pivalate ( Preparation of d-1)

54 mg (40%) of the target compound d-1 was obtained in the same manner as in Step 1 of Example 1, except that compound c-1 was used instead of iodobenzene.

Step 2: (E)-3,3'-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methylbut-1-ene-1,2-diyl)diphenol ( 9 ) manufacture of

1 mg (11%) of target compound 9 was obtained in the same manner as in Step 2 of Example 1, except that compound d-1 was used instead of compound b-1.

^1H NMR (400 MHz, CD ₃ OD) δ 7.18 (t, J = 7.8 Hz, 1H), 7.03-6.97 (m, 1H), 6.90 (d, J = 8.8 Hz, 2H), 6.70 (dt, J = 12.1, 8.3 Hz, 5H), 6.57 (t, J = 7.7 Hz, 3H), 3.75 (d, J = 13.1 Hz, 2H), 3.59–3.47 (m, 3H), 3.21 (t, J = 12.5 Hz) , 2H), 3.02 (m, 1H), 2.90 (t, J = 12.4 Hz, 2H), 1.42 (dd, J = 21.9, 6.7 Hz, 6H), 0.96 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₇ N ₂ O ₂ [M+H] ⁺ 457.29; found 457.32.

[Example 16] (E)-3-(2-(4-hydroxyphenyl)-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methylbut-1-en-1-yl)phenol Preparation of ( 10 )

Step 1: (E)-3-(2-(4-hydroxyphenyl)-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methylbut-1-en-1-yl)phenyl pivalate ( Preparation of d-2)

42 mg (31%) of the target compound d-2 was obtained in the same manner as in Step 1 of Example 1, except that compound c-2 was used instead of iodobenzene.

Step 2: (E)-3-(2-(4-hydroxyphenyl)-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methylbut-1-en-1-yl)phenol ( 10 ) manufacture of

1.8 mg (10%) of the target compound 10 was obtained in the same manner as in Step 2 of Example 1, except that compound d-2 was used instead of compound b-1.

MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₇ N ₂ O ₂ [M+H] ⁺ 457.29; found 457.28.

[Example 17] (Z)-4-(1-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-3-methyl-2-phenylbut-1-en-1-yl)phenol Preparation of ( 26 )

Step 1: (Z)-4-(1-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl pivalate ( Preparation of f-1)

Compound a-5 was used instead of compound a-1, and instead of 1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine 19 mg (99%) of the target compound f-1 was obtained in the same manner as in step 1 of Example 1, except that compound e-1 was used.

Step 2: (Z)-4-(1-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-3-methyl-2-phenylbut-1-en-1-yl)phenol ( 26 ) manufacture of

17 mg (quant.) of the target compound 26 was obtained in the same manner as in Step 2 of Example 1, except that compound f-1 was used instead of compound b-1.

MS (ESI ⁺ ) m/z calcd for C ₂₉ H ₃₆ N ₃ O [M+H] ⁺ 442.29; found 442.14.

[Example 18] Preparation of (E)-3-(3-methyl-2-phenyl-1-(4-(piperazin-1-yl)phenyl)but-1-en-1-yl)phenol ( 28 )

Step 1: (E)-tert-butyl 4-(4-(3-methyl-2-phenyl-1-(3-(pivaloyloxy)phenyl)but-1-en-1-yl)phenyl)piperazine-1- Preparation of carboxylate (f-2)

Example 1 except that compound e-2 was used instead of 1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine 0.11 g (15%) of the target compound f-2 was obtained in the same manner as in step 1 of

Step 2: (E) -3- (3-methyl-2-phenyl-1- (4- (piperazin-1-yl) phenyl) but-1-en-1-yl) phenyl pivalate (f-3) manufacturing

After putting compound f-2 (0.11 g, 0.18 mmol) in DCM (3 mL) and adding TFA (141 μL, 1.84 mmol), the mixture was stirred at room temperature for 12 hours. The residue obtained by distilling the reaction solution under reduced pressure was purified using column chromatography to obtain 49 mg (56%) of the target compound f-3.

Step 3: (E)-3-(3-methyl-2-phenyl-1-(4-(piperazin-1-yl)phenyl)but-1-en-1-yl)phenol ( 28 ) manufacture of

3 mg (5%) of the target compound 28 was obtained in the same manner as in Step 2 of Example 1, except that compound f-3 was used instead of compound b-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.23-7.15 (m, 3H), 7.13-7.07 (m, 3H), 6.84-6.78 (m, 2H), 6.75 (d, J = 7.6 Hz, 1H) , 6.73–6.66 (m, 2H), 6.59 (d, J = 8.8 Hz, 2H), 3.02–2.94 (m, 4H), 2.94–2.84 (m, 4H), 0.95 (d, J = 6.9 Hz, 6H) ); MS (ESI ⁺ ) m/z calcd for C ₂₇ H ₃₁ N ₂ O [M+H] ⁺ 399.25; found 399.19.

[Example 19] (E) -3- (1- (4- (1-isopropylpiperidin-4-yl) phenyl) -3-methyl-2-phenylbut-1-en-1-yl) phenol ( 24 ) manufacturing

Step 1: (E)-tert-butyl 4-(4-(3-methyl-2-phenyl-1-(3-(pivaloyloxy)phenyl)but-1-en-1-yl)phenyl)piperidine-1- Preparation of carboxylate (g-1)

Example 1 except that compound e-3 was used instead of 1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine 0.18 g (22%) of target compound g-1 was obtained in the same manner as in step 1 of

Step 2: (E)-3-(3-methyl-2-phenyl-1-(4-(piperidin-4-yl)phenyl)but-1-en-1-yl)phenyl pivalate (g-2) manufacturing

0.14 g (quant.) of the target compound g-2 was obtained in the same manner as in Step 2 of Example 18, except that compound g-1 was used instead of compound f-2.

Step 3: (E)-3-(1-(4-(1-ethylpiperidin-4-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl pivalate (g-3) manufacture of

Compound g-2 (56 mg, 0.12 mmol), acetone (25 μL, 0.35 mmol), NaBH(OAc) ₃ (74 mg, 0.35 mmol), and acetic acid (13 μL, 0.23 mmol) were added to DCE (3 mL). added and stirred at room temperature for 1 hour. Water and ethyl acetate were further added to the reaction mixture to extract an organic layer. The organic layer was dried over anhydrous Na ₂ SO ₄ and filtered. The residue obtained by distilling the solvent under reduced pressure was purified using column chromatography to obtain 15 mg (24%) of the target compound g-3.

Step 4: (E)-3-(1-(4-(1-isopropylpiperidin-4-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenol ( 24 ) manufacture of

2.5 mg (9%) of the target compound 24 was obtained in the same manner as in Step 2 of Example 1, except that compound g-3 was used instead of compound b-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.20-7.12 (m, 3H), 7.11-7.05 (m, 3H), 6.92-6.86 (m, 4H), 6.77-6.72 (m, 1H), 6.69 ( dd, J = 4.2, 2.1 Hz, 2H), 3.55–3.43 (m, 2H), 3.12–2.99 (m, 2H), 2.77–2.63 (m, 1H), 2.09–1.94 (m, 2H), 1.86– 1.75 (m, 2H), 1.35 (d, J = 6.7 Hz, 7H), 0.94 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₈ NO [M+H] ⁺ 440.30; found 440.24.

[Example 20] (E) -4- (1- (4- (1-isopropylpiperidin-4-yl) phenyl) -3-methyl-2-phenylbut-1-en-1-yl) phenol ( 25 ) manufacturing

Step 1: (E)-tert-butyl 4-(4-(3-methyl-2-phenyl-1-(4-(pivaloyloxy)phenyl)but-1-en-1-yl)phenyl)piperidine-1- Preparation of carboxylate (h-1)

Compound a-3 was used instead of compound a-1, and instead of 1-isopropyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperazine 0.52 g (80%) of target compound h-1 was obtained in the same manner as in step 1 of Example 1, except that compound e-3 was used.

Step 2: (E) -4- (3-methyl-2-phenyl-1- (4- (piperidin-4-yl) phenyl) but-1-en-1-yl) phenyl pivalate (h-2) manufacturing

0.43 g (quant.) of target compound h-2 was obtained in the same manner as in Step 2 of Example 18, except that compound h-1 was used instead of compound f-2.

Step 3: (E)-4-(1-(4-(1-isopropylpiperidin-4-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl pivalate (h-3) manufacture of

5 mg (33%) of target compound h-3 was obtained in the same manner as in Step 3 of Example 19, except that compound h-2 was used instead of compound g-2.

Step 4: (E)-4-(1-(4-(1-isopropylpiperidin-4-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenol ( 25 ) manufacture of

2 mg (41%) of the target compound 25 was obtained in the same manner as in Step 2 of Example 1, except that compound h-3 was used instead of compound b-1.

¹ H NMR (400 MHz, CD ₃ OD) δ 7.26 (q, J = 8.3 Hz, 2H), 7.20-7.11 (m, 2H), 7.11-7.01 (m, 4H), 6.92-6.82 (m, 2H) , 6.78 (d, J = 8.5 Hz, 1H), 6.69 (d, J = 8.7 Hz, 1H), 6.36 (d, J = 8.7 Hz, 1H), 3.58–3.45 (m, 3H), 3.26–3.18 ( m, 2H), 3.08-3.03 (m, 1H), 2.21 (d, J = 12.8 Hz, 1H), 2.07-2.01 (m, 2H), 1.87-1.76 (m, 1H), 1.38 (dd, J = 12.8 Hz, 1H) . 23.1, 6.7 Hz, 6H), 0.93 (q, J = 3.5, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₈ NO [M+H] ⁺ 440.30; found 440.33.

[Example 21] Preparation of (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylbut-1-en-1-yl)phenol ( 11 )

Step 1: Preparation of (4-hydroxyphenyl)(4-(4-isopropylpiperazin-1-yl)phenyl)methanone (j-1)

Compound i-1 (0.73 g, 3.38 mmol) and 1-isopropylpiperazine (0.709 mL, 4.06 mmol) were added to DMSO (8 mL), DIPEA (0.709 mL, 4.06 mmol) was added, and the mixture was heated at 120 ° C for 12 hours. . The residue obtained by distilling the reaction solution under reduced pressure was purified using column chromatography to obtain 1.1 g (quant.) of the target compound J-1.

Step 2: (E)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylbut-1-en-1-yl)phenol ( 11 ) manufacture of

After putting zinc (16 mg, 0.25 mmol) in THF (1 mL) and lowering the temperature to 0 °C, TiCl ₄ (14 μL, 0.12 mmol) was slowly added. After heating the reaction solution at 60 °C for 2 hours, compound j-1 (10 mg, 0.031 mmol) and compound k-1 (5 mg, 0.037 mmol) were added thereto. The reaction solution was heated at 50°C for 1 hour. The reaction mixture was poured into a 10% aqueous solution of potassium carbonate, stirred for 30 minutes, and filtered using Celite. After extracting the filtrate with ethyl acetate, the organic layer was dried over anhydrous Na ₂ SO ₄ and filtered. The residue obtained by distilling the solvent under reduced pressure was purified by column chromatography to obtain 1 mg (7%) of the target compound 11 .

[Example 22] (E) -1-isopropyl-4- (4- (1- (4-methoxyphenyl) -4-methyl-2-phenylpent-1-en-1-yl) phenyl) piperazine ( 17 ) manufacturing

Step 1: Preparation of (4-(4-isopropylpiperazin-1-yl)phenyl)(4-methoxyphenyl)methanone (j-2)

1.33 g (90%) of the target compound j-2 was obtained in the same manner as in Example 21, step 1, except that compound i-2 was used instead of compound i-1.

Step 2: (E)-1-isopropyl-4-(4-(1-(4-methoxyphenyl)-4-methyl-2-phenylpent-1-en-1-yl)phenyl)piperazine ( 17 ) manufacture of

12 mg of the target compound 17 (26%, E /Z = 3:1).

¹ H NMR (400 MHz, CD ₃ OD) δ 7.18-7.08 (m, 7H), 6.93 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 6.81 (d, J = 8.9 Hz, 2H), 3.82 (s, 3H), 3.78 (d, J = 12.9 Hz, 2H), 3.63-3.57 (m, 3H), 3.37-3.28 (m, 2H), 3.19 (t, J = 12.5 Hz, 2H), 2.37 (d, J = 7.3 Hz, 2H), 1.55-1.48 (m, 1H), 1.42 (d, J = 6.6 Hz, 6H), 0.82 (d, J = 6.6 Hz, 6H) ; MS (ESI ⁺ ) m/z calcd for C ₃₂ H ₄₀ N ₂ O [M+H] ⁺ 469.31; found 469.16.

[Example 23] Preparation of (E)-1-isopropyl-4-(4-(1-(4-methoxyphenyl)-2-phenylhex-1-en-1-yl)phenyl)piperazine ( 18 )

12 mg of the target compound 18 (25%, E /Z = 4:1).

¹ H NMR (400 MHz, CD ₃ OD) δ 7.22-7.08 (m, 8H), 6.93 (d, J = 8.4 Hz, 2H), 6.88-6.81 (m, 3H), 3.83 (s, 3H), 3.79 (d, J = 13.4 Hz, 2H), 3.63–3.58 (m, 3H), 3.41–3.33 (m, 2H), 3.21 (t, J = 12.4 Hz, 2H), 2.49–2.42 (m, 2H), 1.42 (d, J = 6.5 Hz, 6H), 1.36–1.17 (m, 4H), 0.80 (t, J = 7.1 Hz, 3H); MS (ESI ⁺ ) m/z calcd for C ₃₂ H ₄₀ N ₂ O [M+H] ⁺ 469.31; found 469.15.

[Example 24] Preparation of (E)-1-isopropyl-4-(4-(1-(4-methoxyphenyl)-2-phenylprop-1-en-1-yl)phenyl)piperazine ( 19 )

Compound 19 17 mg (36%, E /Z = 3:1).

¹ H NMR (400 MHz, CD ₃ OD) δ 7.37-7.19 (m, 3H), 7.18-7.05 (m, 5H), 7.04-6.90 (m, 5H), 3.83 (s, 3H), 3.81-3.76 ( m, 2H), 3.70-3.62 (m, 3H), 3.60-3.44 (m, 5H), 1.96-1.83 (m, 4H), 1.74-1.63 (m, 1H), 1.49-1.38 (m, 7H); MS (ESI ⁺ ) m/z calcd for C ₃₂ H ₃₈ N ₂ O [M+H] ⁺ 467.30; found 467.06.

[Example 25] Preparation of (E)-1-(4-(2-cyclopentyl-1-(4-methoxyphenyl)-2-phenylvinyl)phenyl)-4-isopropylpiperazine ( 20 )

27 mg of the target compound 20 (56%, E /Z = 5:1).

¹ H NMR (400 MHz, CD ₃ OD) δ 7.23-7.14 (m, 5H), 7.12-7.05 (m, 3H), 7.00-6.92 (m, 5H), 3.82 (s, 3H), 3.79-3.73 ( m, 2H), 3.67-3.57 (m, 3H), 3.52-3.39 (m, 4H), 3.04-2.91 (m, 1H), 1.75-1.61 (m, 3H), 1.51-1.34 (m, 11H); MS (ESI ⁺ ) m/z calcd for C ₃₃ H ₄₀ N ₂ O [M+H] ⁺ 481.31; found 481.15.

[Example 26] Preparation of (E)-1-(4-(2-cyclohexyl-1-(4-methoxyphenyl)-2-phenylvinyl)phenyl)-4-isopropylpiperazine ( 21 )

Compound 21 17 mg (33%, E /Z = 19:1).

¹ H NMR (400 MHz, CD ₃ OD) δ 7.21-7.13 (m, 4H), 7.11-7.04 (m, 3H), 6.96-6.89 (m, 4H), 6.81 (d, J = 8.6 Hz, 2H) , 3.83 (s, 3H), 3.75 (d, J = 13.1 Hz, 2H), 3.62–3.53 (m, 3H), 3.37–3.30 (m, 2H), 3.20 (t, J = 12.4 Hz, 2H), 2.74-2.61 (m, 1H), 1.76-1.60 (m, 4H), 1.58-1.49 (m, 1H), 1.41 (d, J = 6.6 Hz, 6H), 1.21-1.07 (m, 4H), 1.00- 1.87 (m, 1H); MS (ESI ⁺ ) m/z calcd for C ₃₄ H ₄₂ N ₂ O [M+H] ⁺ 495.33; found 495.60.

[Example 27] (E)-1-isopropyl-4-(4-(3-methyl-1-(4-(methylthio)phenyl)-2-phenylbut-1-en-1-yl)phenyl)piperazine ( 22 ) manufacturing

Step 1: Preparation of (4-(4-isopropylpiperazin-1-yl)phenyl)(4-(methylthio)phenyl)methanone (j-3)

0.19 g (56%) of target compound j-3 was obtained in the same manner as in step 1 of Example 21, except that compound i-3 was used instead of compound i-1.

Step 2: (E)-1-isopropyl-4-(4-(3-methyl-1-(4-(methylthio)phenyl)-2-phenylbut-1-en-1-yl)phenyl)piperazine ( 22 ) manufacture of

9 mg (18%) of the target compound 22 was prepared in the same manner as in Step 2 of Example 21, except that compound j-3 was used instead of compound j-1 and compound k-7 was used instead of compound k-1. got it

¹ H NMR (400 MHz, CD ₃ OD) δ 7.29 (d, J = 8.1 Hz, 2H), 7.21-7.17 (m, 4H), 7.13-7.08 (m, 3H), 6.91 (d, J = 8.5 Hz , 2H), 6.76 (d, J = 8.6 Hz, 2H), 3.74 (d, J = 13.3 Hz, 2H), 3.62–3.54 (m, 3H), 3.29–3.26 (m, 2H), 3.12 (t, J = 12.3 Hz, 2H), 3.06–3.00 (m, 1H), 2.50 (s, 3H), 1.40 (d, J = 6.6 Hz, 6H), 0.96 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₁ H ₃₈ N ₂ S [M] ⁺ 470.28; found 470.80.

[Example 28] (Z)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)-N,N- Preparation of dimethylaniline ( 23 )

Step 1: Preparation of (4-(dimethylamino)phenyl)(4-(4-isopropylpiperazin-1-yl)phenyl)methanone (j-4)

0.17 g (63%) of the target compound j-4 was obtained in the same manner as in Example 21, step 1, except that compound i-4 was used instead of compound i-4.

Step 2: (Z)-4-(1-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-2-phenylbut-1-en-1-yl)-N,N-dimethylaniline ( 23 ) manufacture of

Compound 23 6 mg (12%, E /Z = 19:1).

¹ H NMR (400 MHz, CD ₃ OD) δ 7.33 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 7.20-7.11 (m, 9H), 3.95 (d, J = 13.2 Hz, 2H), 3.67–3.60 (m, 3H), 3.41–3.32 (m, 2H), 3.25 (t, J = 12.4 Hz, 2H), 3.15 (s, 6H), 3.09–3.02 (m, 1H), 1.46 (d, J = 6.6 Hz, 6H), 0.97 (d, J = 6.8 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₂ H ₄₁ N ₃ [M+H] ⁺ 468.33; found 468.10.

[Example 29] (Z)-5-(1-(3-hydroxyphenyl)-3-methyl-2-phenylbut-1-en-1-yl)-2-(4-isopropylpiperazin-1-yl)phenol ( 29 ) manufacturing

Step 1: (Z)-1-isopropyl-4-(2-methoxy-4-(1-(3-methoxyphenyl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl)piperazine (j -5) Preparation of

6 mg (8%) of the target compound j-5 was obtained in the same manner as in Step 1 of Example 21, except that compound i-5 was used instead of compound i-4.

Step 2: 1-isopropyl-4-(2-methoxy-4-((Z)-1-(3-methoxyphenyl)-3-methyl-2-phenylbut-1-enyl)phenyl)piperazine (m-1) manufacturing

Compound m-1 6 mg (8% ) was obtained.

Step 3: (Z)-5-(1-(3-hydroxyphenyl)-3-methyl-2-phenylbut-1-en-1-yl)-2-(4-isopropylpiperazin-1-yl)phenol ( 29 ) manufacture of

1 mg (30%) of the target compound 29 was obtained in the same manner as in Example 12, except that compound m-1 was used instead of compound 6.

^1H NMR (400 MHz, CD ₃ OD) δ 7.17 (t, J = 7.4 Hz, 3H), 7.10 (dd, J = 8.9, 7.5 Hz, 3H), 6.73 (d, J = 7.5 Hz, 1H), 6.69 (d, J = 6.2 Hz, 2H), 6.60 (d, J = 8.2 Hz, 1H), 6.47 (d, J = 1.8 Hz, 1H), 6.43 (dd, J = 8.2, 1.9 Hz, 1H), 3.55-3.48 (m, 1H), 3.41 (t, J = 14.9 Hz, 4H), 3.24 (d, J = 9.9 Hz, 2H), 3.06-2.99 (m, 1H), 2.85 (t, J = 11.7 Hz) , 2H), 1.37 (d, J = 6.6 Hz, 6H), 0.93 (d, J = 6.9 Hz, 6H); MS (ESI ⁺ ) m/z calcd for C ₃₀ H ₃₇ N ₂ O ₂ [M+H] ⁺ 457.29; found 457.20.

[Experimental Example 1] ERRγ, ERRα, ERRβ, ERα binding assay (binding assay)

1) ERRγ binding assay (inverse agonist assay)

Starting from a final concentration of 10 μM, the compound of the present invention was sequentially added to a 384 well plate so that the concentration was diluted by a factor of two. Then, GST-coupled ERR gamma LBD (ligand-binding domain) was added to a final concentration of 5 nM, and fluorescien-conjugated coacitivator PGC1a and Tb-a-GST antibody were added to 500 nM and 5 nM, respectively. After all reagents were added, the mixture was reacted while gently shaking at 20 ° C. for 1 hour, and the binding activity after reaction was measured by TR-FRET method. That is, after excitation was performed at 340 nm and emission values were measured at 495 nm and 520 nm, respectively, the result analysis was performed as 490 nm measurement value/520 nm measurement value, and Prism 6 was used as an analysis program.

2) ERRα / ERRβ / ERα binding assay (selectivity test)

ERR alpha binding assay used ERR alpha LBD coupled with GST, and all other experimental methods were the same as those of ERR gamma binding assay.

For the ERR beta binding assay, GST-conjugated ERR alpha LBD was used at a final concentration of 10 nM and fluorescien-conjugated coacitivator PGC1a at a final concentration of 250 nM, and all other experimental methods were the same as those of the ERR gamma binding assay.

In the ER alpha binding assay, GST-bound ER alpha LBD (ligand-binding domain) was added to a 384 well plate to which the compound of the present invention was added, to a final concentration of 7.3 nM. In addition, fluorescien-conjugated coacitivator PGC1a and Tb-a-GST antibody were added at 250nM and 5nM, respectively, and beta-estradiol, an agonist, was added to a final concentration of 4nM. All subsequent experimental methods were identical to those of the ERR gamma binding assay.

[Experimental Example 2] ERRγ inverse agonist functional assay

AD293 was cultured for 24 hours in a 24 well plate using DMEM High Glucose (Hyclone, USA) medium supplemented with 0.5% FBS at a concentration of 9 × 10 ⁴ cells/well. Replace with DMEM High Glucose medium supplemented with 10% FBS, mix Trans IT-LT1 transfection reagent (Mirus, USA), pCMX-Gal4-ERRγ, pFR-luciferase reporter plasmid, and pCMV-β-gal and treat together. time incubated. Thereafter, luciferase activity assay and β-gal assay were performed with the lysate obtained after treatment with the compound of the present invention for 24 hours, respectively. All results were derived from at least three independent and repeated experiments.

The results of Experimental Example 1 and Experimental Example 2 are shown in Tables 1 and 2 below.

ERRγ/ERRβ binding assay (concentration: 10 μM) compound number Binding assay at 10 μM, (% of control) ERRγ ERRβ One 4.98 0 4 3.03 2.744 10 2.8 4.7 11 6.6 3.5 12 2.63 0 13 6.74 1.86 19 3.5 -9.0 20 2.1 -2.9 22 3.1 -2.0

ERRγ/ERRα/ERRβ binding assay and ERRγ inverse agonist function assay (IC ₅₀ ) compound number Binding Assay, IC ₅₀ (μM) functional assays,
IC ₅₀ (μM) ERRγ ERRα ERRβ ERα ERRγ One 0.023 0.850 0.033 0.730 0.010 12 0.021 >10 0.010 0.088 0.004 13 0.026 >10 0.018 0.165 0.005

[Experimental Example 3] In vivo pharmacokinetics (in vivo PK) evaluation

In order to examine the pharmacokinetic behavior of the compound of the present invention when intravenously or orally administered to rats, the following experiment was conducted using rats weighing at least 200 g, and the results are shown in Table 3 below.

go. Experiment method

1. The oral administration group is fasted one day before

2. Time 0 blood is drawn from each animal

3. Inject the drug into the intravenous administration group (IV) through the tail vein at a dose of 1mg/kg (syringe).

4. Inject the drug orally at a dose of 10 mg/kg to the oral administration group (PO) (oral zondec).

5. In the case of the intravenous administration group after administration, 9 blood samples were collected from the jugular vein at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours. The amount of blood drawn once is 200ul.

6. After administration, in the case of the oral administration group, blood is drawn 10 times from the jugular vein at 0.25, 0.5, 1, 4, 6, 8, 10, and 24 hours. The amount of blood drawn once is 200ul.

7. Put each blood into a K2EDTA tube and keep on ice.

8. Collect the supernatant plasma through centrifugation.

9. Analyze the drug by injecting it into the LC-MS/MS system.

compound number administration group AUC _all
(µMh) AUC _-INF
(µMh) BA
(%) C _max
(μM) Cl(observed)/F
(mL/min/kg) T _max (h) t _1/2 (h) V _ss (L/Kg) FW One IV 1.88 1.95 66.2 16.2 5.45 5.57 529.55 PO 12.44 12.70 1.33 3 4.06

[Experimental Example 4] colorectal cancer, ovarian cancer, prostate cancer, breast cancer, neuroblastoma, Experiments on undifferentiated and dedifferentiated thyroid cancer

1. Materials and Methods

1.1. Bioinformatics analysis

A colorectal cancer data set obtained from the Oncomine database was used for ERRβ/γ gene analysis.

1.2. Analysis of clinical tissue samples

A tumor microarray (TMA; BC051110c) was purchased from US Biomax, Inc. for histological analysis. Representative areas of cancerous lesions were carefully selected from sections stained with hematoxylin and eosin, and two tissue cores (2 mm in diameter) were obtained from each paraffin block. Immunohistochemical (IHC) staining of TMA was performed using anti-human ERR gamma (mouse monoclonal antibody; PP-H6812-00; dilution 1:100; R&D systems, Minneapolis, MN) and anti-human ERR beta (mouse monoclonal antibody). ;PP-H6707-00;dilution 1:100;R&D systems, Minneapolis, MN).

1.3. animal

Specific pathogen-free (SPF), 6-week-old male Balb/c nude mice and immunocompetent Balb/c mice were purchased from SLC, Inc. All animal experimental procedures were maintained and used in accordance with the Guidelines for Care and Use of Laboratory Animals of the Laboratory Animal Center Research Institute of Daegu Gyeongbuk Medical Innovation Foundation. Animal experiments were conducted after the approval of the Institutional Review Board for Ethics of Animal Experiments, Daegu Gyeongbuk Medical Innovation Foundation (approval number: DGMIF-19020701-00).

1.4. cell

HCT-116, RKO, SW480, CT26, PC-3, A2780, MDA-MB231, MCF-7, BE2C, CAL62, BHT101, BHP103scp, BcPAP and Human fibroblast (BJ) cells were purchased from American Type Culture Collection (ATCC) did

A2780, HCT-116, RKO, CT26, PC3, MDA-MB231, MCF-7, BHP103scp and SW480 cells maintained in RPMI 1640 supplemented with 10% FBS (Gibco FBS; Thermo Fisher Scientific) and 1% streptomycin/penicillin It became. BJ cells were cultured in high-glucose Dulbecco modified Eagle medium containing 10% fetal bovine serum (FBS) and 1% streptomycin/penicillin. BE2C was maintained in DMEM:F-12 supplemented with 10% FBS and 1% streptomycin/penicillin. CAL62 and BcPAP were maintained in DMEM supplemented with 10% FBS and 1% streptomycin/penicillin. BHT101 was maintained in DMEM supplemented with 20% FBS and 1% streptomycin/penicillin. All cells were grown at 37°C and 5% CO ₂ atmosphere. Mycoplasma testing was performed regularly monthly using the BioMycoX Mycoplasma PCR Detection Kit (CellSafe).

1.5. Cell viability assay

Cell viability was analyzed using Cell Counting Kit-8 (Dojindo molecular technologies, MD, USA). Each cell was seeded in a 96-well plate and treated with Compound 1 (DN203368) or Compound 12 (DN3317) at different concentrations. At the indicated time points, CCK-8 (10 μL/well) reagent was added to the cells, followed by further incubation at 37° C. for 90 minutes. Absorbance at 450 nm was measured using a plate reader (BioTek Instruments, Winooski, USA).

1.6. western blot

For total protein extraction, the cells were treated with Compound 1 (DN203368) for 24 hours in a 37°C, CO ₂ incubator, and washed twice with PBS (phosphate-buffered saline). Cell pellets were lysed using radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific, IL, USA) containing protease and phosphatase inhibitor cocktail kit (Thermo Fisher Scientific). The lysed cells were briefly vortexed at intervals and then centrifuged at 13,000 xg at 4°C. Protein samples were quantified with a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific).

Equal amounts of protein were loaded on 10% SDS (sodium dodecyl sulfate)-PAGE (polyacrylamide gel electrophoresis) and transferred to a PVDF membrane (Millipore, Billerica, MA, USA). Membranes were blocked with 5% skim milk in TBS (Tris-buffered saline) containing TBS-T (Tween-20) for 1 hour and probed with primary antibodies in 5% BSA overnight at 4°C. After incubation, the membrane was probed with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at room temperature. The membrane was washed three times with TBS-T, and signals were visualized using enhanced chemiluminescence (ECL) detection reagent (GE Healthcare Life Sciences, Pittsburgh, PA, USA).

The primary antibodies used were as follows: ERRβ (R&D systems), ERRγ (R&D systems), PARP (Cell signaling; working dilution 1:1000), cleaved caspase3 (Cell signaling; dilution 1:1000), acetyl-p53 (Cell signaling; working dilution 1:1000). Signaling; dilution 1:1000), Bcl-2 (Cell Signaling; dilution 1:1000), BID (Cell Signaling; dilution 1:1000), p21 (Cell Signaling; dilution 1:1000), Cyclin D1 (Cell Signaling; dilution 1:1000) 1:1000), CDK4 (Cell Signaling; dilution 1:1000), and β-actin (Cell Signaling; dilution 1:5000).

The HRP-conjugated secondary antibodies used were: anti-mouse (Cell Signaling) and anti-rabbit (Cell Signaling).

1.7. Cell-cycle analysis

Washed and fixed cells were stained with 0.5 mL PI (propidium iodide)/RNase staining buffer in the dark for 15 minutes at room temperature. DNA content, cell cycle profile and forward scatter (FSC) were analyzed using a Becton Dickinson LSRFortessa ^™ (BD Diagnostics) with emission detection at 488 nm (excitation) and 575 nm (peak emission). Data were analyzed using FlowJo (BD biosciences).

1.8. Apoptosis analysis

Cells were washed with PBS containing 1% HS (horse serum), and stained with FITC-Annexin V apoptosis detection kit I (BD Biosciences) at room temperature for 30 minutes in the dark. DNA content, cell cycle profile and forward scatter profile were determined using a Becton Dickinson LSRFortessa ^™ and analyzed with FlowJo software.

1.9. Caspase3/7 activity assay

After treatment with Compound 1 (DN203368), caspase3/7 activity was measured using the luminescent Caspase-Glo3/7 (Promega) assay according to the manufacturer's instructions. That is, each of the HCT-116, SW480, and RKO cells were seeded in a white-walled 96-well culture plate at a density of 10 ⁴ /well. Cells were treated at various time points after compound 1 (DN203368) treatment. After incubation, 100 μL Caspase-Glo3/7 reagent was added to each sample. The degree of luminescence was measured using IVIS Lumina III.

1.10. In vivo therapy ( In vivo therapy)

Cells HCT116, RKO, SW480, CT26, BE2C, A2780, MDA-MB231 and BHP103scp were inoculated subcutaneously into mice at 2 × 10 ⁶ each. For breast cancer orthotopic implantation, MDA-MB231 cells were injected into the mammary fat pad just below the nipple under anesthesia. When tumor formation was found by inspection and palpation, compound 1 (DN203368) was administered intraperitoneally or orally once a day for 10 days.

Vehicle information is as follows: vehicle solution is 10% DMSO, 15% DW and 75% PEG (for intraperitoneal injection), 0.5% methyl cellulose solution (for oral administration).

Tumor size was measured with calipers at designated time points, and tumor volume (mm ³ ) was calculated using the formula below.

Tumor volume (mm ³ ) = d2 × D/2

where d and D are the shortest and longest diameters in mm, respectively.

Resected HCT116, RKO, SW480 and BHP103scp tumors were excised and fixed in 10% formalin for further experiments.

1.11. H&E staining and IHC

After fixation in formalin, paraffin-embedded tissues were cut into sections according to standard H&E staining protocols. Paraffin-embedded sections of SW480, RKO, and BHP103scp tumor tissues, respectively, were deparaffinized, hydrated, and subjected to antigen retrieval for IHC staining. Endogenous peroxidase was inactivated by hydrogen peroxide for 10 minutes. Tumor tissue sections were mixed with rabbit monoclonal anti-Ki-67 (1:200, ab16667; Abcam) and rabbit polyclonal anti-cleaved caspase-3 (9661, #1:200 dilution, Cell Signaling, Boston, MA) according to the manufacturer's instructions. USA). A DAB detection kit (Pierce, Rockland, IL, USA) was used for visualization.

1.12. Statistical Analysis

All data are presented as mean ± standard deviation (SD), and statistical significance was determined using the unpaired Student's test in GraphPad Prism 5 (La Jolla, CA, USA). A P value of less than 0.05 was considered statistically significant.

2. Results

2.1. Up-regulation of ERRβ and ERRγ in colorectal cancer

In order to investigate the clinical correlation between ERRβ/γ expression and colorectal cancer carcinogenesis, we analyzed ERRβ/γ expression in colorectal cancer patients using the Oncomine database. Higher levels were found in tissues.

As a result of observing ERRβ/γ expression in both normal and tumor tissues using Western blotting, it was confirmed that ERRβ/γ expression was up-regulated in tumor tissues rather than normal tissues (FIG. 1A and B).

A commercial tumor microarray (BC051110c, containing 12 normal tissues and 108 tumor tissues) obtained from colorectal cancer patients was used to determine the difference in ERRβ/γ protein expression between human colorectal cancer and normal colorectal tissues. As a result of tissue microarray (TMA) analysis using an ERRβ/γ-specific antibody, colorectal cancer tissue showed a higher level of ERRβ/γ expression than normal tissue (FIG. 1C).

These results indicate that ERRβ/γ is related to the pathophysiological characteristics of colorectal cancer, confirming that ERRβ/γ is a promising therapeutic target for colorectal cancer in vivo.

2.2. Inhibition of colon cancer cell proliferation by Compound 1 (DN203368)

The inhibitory effect of compound 1 (DN203368) on the proliferation of different types of colorectal cancer cells with different mutations, such as HCT116, RKO, SW480 and CT26 cells, was investigated.

Before evaluating the antiproliferative effect of compound 1 (DN203368) in vitro , Western blotting analysis was performed using a specific antibody of ERRβ/γ to determine the level of endogenous expression of ERRβ/γ. As shown in FIG. 2 , differential endogenous expression levels of ERRβ/γ were found in colon cancer cells. The results of the CCK-8 assay showed that Compound 1 (DN203368) induced dose-dependent inhibition of colon cancer cell proliferation (FIGS. 4 and 5). The concentrations that induced 50% cell growth inhibition (GI ₅₀ ) were 3.5 μM, 4.9 μM, 3.9 μM, and 2.2 μM in HCT-116, SW480, RKO, and CT26 cells, respectively (FIG. 6). However, no anti-proliferative effect was observed in normal cells such as fibroblasts (BJ cells) and epithelial cells (CHO cells) (FIG. 3). From the above results, the selective cytotoxicity of Compound 1 (DN203368) in colon cancer cells was confirmed.

Oxaliplatin and 5-fluorouracil (5-FU) are widely applied alone or in combination with other treatments as first-line treatments for colorectal cancer cells. As a result of comparing the conventional anticancer drug and Compound 1 (DN203368) in colon cancer cells, the antiproliferative effect in cells treated with Compound 1 (DN203368) was higher than that in cells treated with conventional anticancer drugs oxaliplatin or 5-FU (FIG. 7). and Figure 8).

2.3. Induction of compound 1 (DN203368)-mediated cell cycle arrest and apoptosis in colon cancer cells

Compound 1 (DN203368) did not show any cytotoxicity in normal fibroblasts and epithelial cells at 5 μM and 10 μM. We investigated whether compound 1 (DN203368)-mediated inhibition of colorectal cancer cells was related to cell cycle arrest and induction of apoptosis.

Along with cell proliferation inhibition, cell cycle analysis demonstrated a dose-dependent increase in the sub-G1 fraction in Compound 1 (DN203368)-treated cells (FIG. 9). FACS analysis using Annexin V and PI showed significant upregulation of the apoptotic fraction (AF) in a dose-dependent manner in compound 1 (DN203368)-treated cells, unlike vehicle-treated cells ( Figure 10).

2.4. Activation of caspase-3-dependent apoptosis in colon cancer cells through upregulation of p53 acetylation

In order to confirm the signaling pathway associated with the anti-proliferative effect of Compound 1 (DN203368) in colon cancer cells, the endogenous expression level of ERRβ/γ was examined in Compound 1 (DN203368)-treated colon cancer cells. A decrease in ERRβ expression was dose-dependent in Compound 1 (DN203368)-treated cells. Similarly, ERRγ was found to be down-regulated by Compound 1 (DN203368) in colon cancer cells (FIG. 11A).

To identify other pathways involved in Compound 1 (DN203368)-mediated apoptosis, an antibody array comprising 1318 site-specific and phospho-specific antibodies in 30 signaling pathways was used for Compound 1 (DN203368)- This was performed using treated SW480 colorectal cancer cells. Significant changes in p53 phosphorylation and proteins regulating cell cycle and apoptosis were found in Compound 1 (DN203368)-treated cells.

Western blot analysis further confirmed the up- or down-regulated proteins found in the antibody array. Cell cycle arrest and induction of apoptosis represent the most prominent biological consequences of p53 activation. As a result of analyzing the acetylation status of p53 as a tumor suppressor after treatment with Compound 1 (DN203368), as shown in FIG. higher in cells. Cell cycle arrest by p53 is mainly mediated by transcriptional activation of p21/WAF1. As shown in FIG. 11B , it was found that p21 (a cell cycle inhibitor) was increased in compound 1 (DN203368)-treated colon cancer cells. p21 binds to cyclin E/Cdk2 and cyclin D/Cdk4 complexes to induce cell cycle G1-phase arrest, and downregulation of CDK4 and cyclin D1 was confirmed in Compound 1 (DN203368)-treated cells.

Apoptosis-related proteins were further identified in Compound 1 (DN203368)-treated colon cancer cells. As shown in FIG. 11C , Bcl-2 (anti-apoptotic protein) was down-regulated in Compound 1 (DN203368)-treated cells, but Compound 1 (DN203368) showed an increase in BID (proapoptotic protein). . In particular, compound 1 (DN203368) treatment resulted in a dose-dependent increase in cleaved caspase 3 and cleaved PARP. In addition, a time-dependent decrease in Bcl-2 as well as an increase in cleaved caspase 3 and cleaved PARP1 were confirmed in Compound 1 (DN203368)-treated HCT116 cells (Fig. 11E).

To confirm whether compound 1 (DN203368)-mediated growth inhibition of colorectal cancer cells is due to the caspase 3-dependent pathway, time- and dose-dependent changes in active caspase 3 were analyzed by Caspase-Glo 3/ 7 assay and Z-VAD (pan-caspase inhibitor). That is, after treatment of colorectal cancer cells with Compound 1 (DN203368), changes in luminescent signals showing the caspase 3/7 level were monitored using an IVIS imaging system. As shown in A and C of FIG. 12 , time- and dose-dependent increases in luminescent signals were detectable in Compound 1 (DN203368)-treated cells. Thus, the decrease in cell viability occurred in a time- and dose-dependent manner in Compound 1 (DN203368)-treated cells (FIG. 12B). On the other hand, the Z-VAD inhibitor down-regulated the increased luminescent signal to the basal level in Compound 1 (DN203368)-treated cells (Fig. 12D).

From the above results, it was confirmed that growth inhibition by compound 1 (DN203368) was related to p53-mediated G1-cell cycle arrest and induction of caspase 3-dependent apoptosis in colon cancer cells.

2.5. in vivo ( in vivo ) Strong antitumor effect induced by compound 1 (DN203368) in a xenograft model of colorectal cancer

In order to evaluate the antitumor effect of Compound 1 (DN203368) in a colorectal cancer model, immunodeficient mice were inoculated with colorectal cancer cells (HCT-116) (FIG. 13A). Compound 1 (DN203368) was administered to HCT116 tumor-bearing mice by intraperitoneal injection once a day for 10 days. As shown in FIG. 13 B and C, vehicle-treated mice exhibited rapid tumor growth during the in vivo study, whereas Compound 1 (DN203368) treatment group dose-dependent inhibition of HCT-116 tumor growth. caused 5 mg/kg Compound 1 (DN203368)-treated mice showed tumor growth inhibitory effect, but no statistical difference from vehicle-treated mice was found. For 10 mg/kg compound 1 (DN203368)-treated mice, significant tumor growth inhibition was observed from day 7 to day 17 post treatment. During in vivo treatment, no abnormal behavior and weight loss were observed in Compound 1 (DN203368)-treated mice (Fig. 13D). Serum biochemical analysis for liver toxicity revealed that the levels of total protein, albumin, total cholesterol, triglyceride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) in blood were significantly different from vehicle-treated mice and Compound 1 ( DN203368) - it was found that there was no significant difference between the treated mice (Fig. 13E).

In order to investigate the therapeutic effect of compound 1 (DN203368) in colorectal cancer models, RKO and SW480, As shown in A of FIG. 14 , compound 1 (DN203368) was administered to each tumor-bearing mouse via intraperitoneal injection every day for 10 days. In the case of the SW480 xenograft, the antitumor effect was first found with a significant difference on the 4th day and continued until the 18th day (FIG. 14B). In the case of RKO xenografts, significant inhibition of tumor growth was found in Compound 1 (DN203368)-treated mice on day 6 after treatment, and antitumor effects were also found on day 16 (FIG. 14C). Abnormal behavior and weight loss were not found during administration of Compound 1 (DN203368) (Fig. 14D and E). SW480 and RKO tumors were excised after in vivo treatment, and immunohistochemical analysis was performed to determine tumor cell proliferation and cleaved caspase-3 levels. As shown in Figure 14F, immunohistochemistry using the Ki-67 antibody as a tumor cell proliferation marker showed higher expression in vehicle-treated SW480 tumors than Compound 1 (DN203368)-treated SW480 tumors. . Immunohistochemical staining with a cleaved caspase-3 antibody showed a greater increase in expression in Compound 1 (DN203368)-treated tumors than in vehicle-treated tumors (FIG. 14 F and G). From this, it was confirmed that Compound 1 (DN203368) can be used as an anticancer agent for treating colon cancer.

2.6. in vivo ( in vivo ) Potential of compound 1 (DN203368) as an oral anti-cancer agent

In order to confirm the antitumor effect of compound 1 (DN203368) on colon cancer through oral administration, an experiment was conducted using a colon cancer model including HCT-116 and CT26 cells as shown in FIG. 15 . Tumor-bearing mice were administered 10 mg/kg Compound 1 (DN203368) via oral administration once a day for 10 days. As shown in FIG. 15B , oral administration of Compound 1 (DN203368) successfully induced an antitumor effect in HCT-116 xenografts, and a significant difference was first observed on day 13 after treatment. In addition, CT26 tumor growth was significantly inhibited in Compound 1 (DN203368)-treated mice, whereas it was not observed in vehicle-treated mice (Fig. 15D). Abnormal behavior and weight loss were not found during the experiment (Fig. 15 C and E). Serum biochemical tests of CT26 tumor-bearing mice showed no significant difference in the levels of liver and kidney toxicity-related biomarkers between vehicle-treated mice and compound 1 (DN203368)-treated mice (FIG. 16). From these results, it was confirmed that compound 1 (DN203368) is useful as an orally active anticancer agent for the treatment of colorectal cancer.

2.7. Inhibition of various tumor cell proliferation by Compound 1 (DN203368)

Various cancer cells other than colorectal cancer, namely prostate cancer (PC-3), ovarian cancer (A2780), breast cancer (MDA-MB231, MCF-7), neuroblastoma (BE2C), undifferentiated and dedifferentiated thyroid cancer (CAL62, BHT101, BHP103scp, The inhibitory effect of Compound 1 (DN203368) on the proliferation of BcPAP) cells was investigated.

The results of the CCK-8 assay showed that Compound 1 (DN203368) induced dose-dependent inhibition of proliferation of prostate, ovarian, breast, neuroblastoma, undifferentiated and dedifferentiated thyroid cancer cells (FIG. 17A and B). However, no anti-proliferative effect was observed in normal cells such as fibroblasts (BJ cells) and epithelial cells (CHO cells) (FIGS. 3 and 17A). From the above results, the selective cytotoxicity of Compound 1 (DN203368) in cells of prostate cancer, ovarian cancer, breast cancer, neuroblastoma, and undifferentiated and dedifferentiated thyroid cancer cells was confirmed.

2.8. in vivo ( in vivo ) Strong antitumor effect induced by compound 1 (DN203368) in xenograft models of neuroblastoma and ovarian cancer

To investigate the therapeutic effect of Compound 1 (DN203368) in a neuroblastoma BE2C xenograft model, Compound 1 (DN203368) was administered to each tumor-bearing mouse via intraperitoneal injection every day for 14 days. The antitumor effect was confirmed from the 14th day and continued until the 30th day, and significance was also confirmed (FIG. 18A).

To investigate the therapeutic effect of Compound 1 (DN203368) in the ovarian cancer A2780 xenograft model, Compound 1 (DN203368) was administered to each tumor-bearing mouse via intraperitoneal injection daily for 14 days. In (DN203368)-treated mice, tumor growth inhibition was found to be significant, and the anti-tumor effect was consistently found even on day 16 (FIG. 18B).

2.9. in vivo ( in vivo ) Strong antitumor effect induced by compound 1 (DN203368) in xenograft model and orthotopic model of breast cancer

In order to examine the therapeutic effect of Compound 1 (DN203368) in the breast cancer MDA-MB231 xenograft model, Compound 1 (DN203368) was administered to each tumor-bearing mouse via intraperitoneal injection every day for 14 days. On day 15 after treatment, tumor growth inhibition was found in compound 1 (DN203368)-treated mice, and anti-tumor effect was also found on day 23, and significance was also confirmed (FIG. 19A).

In order to examine the therapeutic effect of Compound 1 (DN203368) in the breast cancer MDA-MB231 orthotopic transplant model, Compound 1 (DN203368) was administered to each tumor-bearing mouse via intraperitoneal injection every day for 14 days. On day 3 after treatment, significant inhibition of tumor growth was found in Compound 1 (DN203368)-treated mice, and antitumor effect was also found on day 23 (FIG. 19B).

2.10. in vivo ( in vivo ) Strong antitumor effect induced by compound 1 (DN203368) in xenograft model of dedifferentiated thyroid carcinoma

To investigate the therapeutic effect of Compound 1 (DN203368) in a dedifferentiated thyroid carcinoma BHP103scp xenograft model, Compound 1 (DN203368) was administered to tumor-bearing mice via intraperitoneal injection every day for 14 days. On day 8 after treatment, significant inhibition of tumor growth was found in Compound 1 (DN203368)-treated mice, and antitumor effect was also found on day 14 (Fig. 20A). Abnormal behavior and weight loss were not found during administration of Compound 1 (DN203368) (FIG. 20B). BHP103scp tumors were excised after in vivo treatment, and immunohistochemical analysis was performed to determine tumor cell proliferation and cleaved caspase-3 levels. As shown in FIG. 20C , immunohistochemistry using Ki-67 antibody as a tumor cell proliferation marker showed higher expression in vehicle-treated BHP103scp tumors than Compound 1 (DN203368)-treated BHP103scp tumors. . Immunohistochemical staining using a cleaved caspase-3 antibody showed a greater increase in expression in Compound 1 (DN203368)-treated tumors than in vehicle-treated tumors (FIG. 20C).

As described above, it was confirmed that Compound 1 (DN203368) can be used as an anticancer agent for treating various intractable cancers such as colorectal cancer, neuroblastoma, ovarian cancer, breast cancer, and dedifferentiated thyroid cancer.

2.11. Inhibition of various tumor cell proliferation by compound 12 (DN3317)

The inhibitory effect of Compound 12 (DN3317) on the proliferation of prostate cancer (PC-3), ovarian cancer (A2780), glioblastoma (U87MG) and dedifferentiated thyroid cancer (BHP103scp, BcPAP) cells was investigated.

As a result of CCK-8 analysis, it was confirmed that Compound 12 (DN3317) inhibited the proliferation of prostate cancer, ovarian cancer, glioblastoma, and dedifferentiated thyroid cancer cells in a dose-dependent manner (FIG. 21).

2.12. Inhibition of colorectal cancer cell proliferation by combined administration of Compound 1 (DN203368) and anticancer drugs

The purpose of this study was to investigate the inhibitory effect of colorectal cancer cell proliferation by the combined administration of an existing anticancer drug and Compound 1 (DN203368) in colorectal cancer cells (HCT116, SW480 and CT26 cells).

Existing anticancer drugs such as Apatinib, oxaliplatin, and 5-fluorouracil (5-FU) were used.

In colorectal cancer cell line HCT-116 cells, 30μM Afatinib and 5μM DN203368 alone showed cell viability of 83% and 79%, respectively. However, when 30 μM Afatinib and 5 μM DN203368 were simultaneously treated, the cell viability was 27% (A and B in FIG. 22). In colorectal cancer cell line HCT-116 cells treated with 2 µM 5-fluorouracil (5-FU) and 2.5 µM DN203368 alone, cell viability was 70% and 68%, respectively. When 2 μM 5-fluorouracil (5-fluorouracil, 5-FU) and 2.5 μM DN203368 were simultaneously treated, cell viability was 54% (C in FIG. 22). When 0.5 μM oxaliplatin and 2.5 μM DN203368 were treated alone in the colorectal cancer cell line HCT-116 cells, cell viability was 82% and 68%, respectively. When 0.5 μM oxaliplatin and 2.5 μM DN203368 were simultaneously treated, the cell viability was 56% (Fig. 22D).

In the case of colorectal cancer cell line SW480 cells treated with 2 µM 5-fluorouracil (5-FU) and 2.5 µM DN203368 alone, cell viability was 79% and 80%, respectively. When 2 μM 5-fluorouracil (5-fluorouracil, 5-FU) and 2.5 μM DN203368 were simultaneously treated, the cell viability was 49% (FIG. 23A). In colorectal cancer cell line SW480 cells, when 0.5 μM oxaliplatin and 2.5 μM DN203368 were treated alone, cell viability was 92% and 80%, respectively. When 0.5 μM oxaliplatin and 2.5 μM DN203368 were concurrently treated, 68% cell viability was observed (FIG. 23B).

In colorectal cancer cell line CT26 cells, 6 μM Afatinib and 5 μM DN203368 alone showed cell viability of 94% and 70%, respectively, at 24 hours. When 6 μM Afatinib and 5 μM DN203368 were simultaneously treated, the cell viability was 9% (FIG. 24).

As described above, since the ethene compound according to the present invention selectively exhibits high inhibitory activity and antiproliferative effect on cancer cells, it can be usefully used for preventing or treating cancer. In addition, when the ethene compound according to the present invention is used in combination with an existing anticancer agent, the survival rate of cancer cells can be significantly reduced compared to when each is used alone, and the antiproliferative effect can be maintained over a long period of time.

Although the present invention has been described in detail only for the described embodiments, it is obvious to those skilled in the art that various changes and modifications are possible within the scope of the technical idea of the present invention, and it is natural that these changes and modifications fall within the scope of the appended claims. .

Claims (10)

an ethene compound represented by Formula 1 below, a pharmaceutically acceptable salt thereof, or an N-oxide thereof; And a combination preparation for preventing or treating cancer containing an anticancer agent:
[Formula 1]

In Formula 1,
R ¹ is C2-C5 alkyl or C3-C7 cycloalkyl;
R ² is OH, OCH ₃ , SCH ₃ , OCOCH ₃ or N(CH ₃ ) ₂ ;
A ¹ to A ⁴ are each CH;
R ³ is C3 alkyl;
L is CH or N;
m is an integer from 1 to 2, and when m is an integer of 2, R ² may be the same or different;
n is an integer of 0 or 1; delete delete delete delete delete According to claim 1,
Wherein R ¹ is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, t-pentyl, s-pentyl, 3-pentyl, s-isopentyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, a combination formulation. According to claim 1,
The combination preparation, wherein the ethene compound is at least one selected from the following structures:

According to claim 1,
The anticancer agent is Afatinib, oxaliplatin, 5-fluorouracil (5-FU), doxorubicin, paclitaxel, vincristine, daunorubicin, vinblastine , actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, Gleevec (STI-571), cisplatin, 5-fluorouracil, adriamycin, methotrexate, busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard and nitrosoureas At least one selected from the group consisting of (nitrosourea), a combination formulation. According to claim 1,
The ethene compound and the anticancer agent are administered simultaneously or sequentially, the combination preparation.

Images